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ABSTRACT 
 Despite decades of extensive research, breast cancer remains an 
untamable disease due to complexity and heterogeneity of disease. It is for this 
very reason, most efforts targeting a single pathway did not yield satisfactory 
results. Discovery of a novel therapeutic agents targeting multiple pathways, such 
as miRNAs, holds promise for future cancer therapy. This study was aimed to 
explore therapeutic potential of one such microRNA, miR-489. In the first study, 
we identified autophagy as a novel pathway targeted by miR-489 and reported 
ULK1 and LAPTM4B to be a direct of miR-489 target. We showed that miR-489 
mediated autophagy inhibition and autophagosome accumulation is necessary for 
its cytotoxic effect. Furthermore, we demonstrated autophagy inhibition and 
LAPTM4B down regulation as a novel mechanism responsible for miR-489 
mediated doxorubicin sensitization. Finally, we found that miR-489 and LAPTM4B 
levels were inversely correlated in human tumor specimens, and more importantly, 
miR-489 expression levels predict overall survival in patients with 8q22 
amplification (Soni et al.). We then established that miR-489 is an estrogen 
regulated miRNA and is highly expressed in hormone positive breast tumors and 
cell lines. For the first time we reported that miR-489 negatively regulates estrogen 
signaling. Depletion of miR-489 using Anti-miR-489 siRNA or CRISPR-Cas9 
significantly increased proliferation, colony formation ability and stem like cell 
population. Mechanistically, we report that miR-489 modulates estrogen induced 
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estrogen receptor localization into nucleus. We further established that 
downregulation of p38 MAPK is responsible for miR-489’s effect of estrogen 
receptor localization. We showed that estrogen activates p38 MAPK and this 
activated p38 MAPK is necessary for nuclear translocation of estrogen receptor. 
Furthermore, we also report that miR-489 prevents activation of ERα by inhibiting 
its phosphorylation. We demonstrated that miR-489 inhibits ERK and AKT 
activation which are responsible kinase for ERα phosphorylation at Ser 118 and 
Ser 167 site, respectively.  We then demonstrated that miR-489 is lost in tamoxifen 
resistant breast tumors and cell lines and restoration of miR-489 significantly 
inhibits its proliferation and overcomes both de novo and acquired tamoxifen 
resistance. miR-489 exerts this effect through its unique ability to target HER2, 
MAPK and PI3K-AKT signaling pathway at the same time. These data advocates 
strongly for therapeutic potential of miR-489 in ERα positive and tamoxifen 
resistant breast cancer. In summary, our data shows that miR-489 expression is 
inversely correlated with aggressiveness of breast cancer and drug resistance and 
proposes miR-489 as a promising prognostic biomarker or therapeutic agent in 
breast cancer.   
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CHAPTER 1 
INTRODUCTION 
1.1 BREAST CANCER 
A highly dynamic development process exits within the epithelia 
of mammary gland, featuring morphogenetic variation during puberty, pregnancy, 
lactation, and regression. The identification of mammary stem cells (MaSCs) via 
lineage-tracing studies has substantiated a hierarchical organization of 
the mammary epithelia. Due to this massive remodeling, breast tissue is 
particularly sensitive to developing cancer. In fact, with an average lifetime risk of 
8–10%, breast cancer is the most common malignancy in women in the western 
world.  According to cancer statistics, approximately 1.7 million new cases arise 
around the globe every year and 2,66,120 new cases are expected in 2018 in the 
United States (Kubista, 2001).  
Due to its heterogeneity, this disease is distinguished by up to 21 distinct 
histological subtypes and four major molecular subtypes which are biologically 
variable in presentation, response to treatment and outcomes. Gene expression 
profiling have pointed out different genetic variability even among tumors 
belonging to same subtype. Four subtypes are defined based on presence or 
absence of receptor molecules on cell surface which include the presence or 
absence of hormone receptors, (estrogen or progesterone) (HR+/HR-) and over-
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expression of human epidermal growth receptor 2 (HER2+/HER2-). Among this 
luminal A (Banegas et al.) is the most abundant (74%) breast cancers express the 
estrogen (ER+) and/ or the progesterone receptor (PR+) but not HER2 (HER2-) 
(Figure 1.1). These cancers tend to be slow growing and less aggressive than 
other subtypes. This type of cancer is associated with favorable prognosis because 
of hormone receptors have better response to hormonal therapy. Triple negative 
(HR-/HER2-) type consists of about 12% of breast cancer. It is called triple 
negative because of lacking ER, PR and HER2 on their cell receptor. These 
cancers have a poorer short-term prognosis than other breast cancer types due to 
lacking targeted therapies. Luminal B breast cancers are consisting of hormone 
receptor positive and HER2 positive tumor cells. Moreover, this subtype also has 
highly positive Ki67 (indicator of a large proportion of actively dividing cells) cells. 
Luminal B is more aggressive than Luminal A. HER2 enriched (HR-/HER2+) breast 
cancers have HER2 over expressing tumor cells. They are mostly hormone 
receptor negative. These cancers tend to grow and spread more aggressively than 
other breast cancers and are associated with poorer short-term prognosis compare 
to ER+ breast cancers.  
1.2 MIRNA 
miRNAs belong to a small non-coding regulatory RNAs that are 18-24 
nucleotide long single stranded highly conserved RNA molecules. They are 
synthesized from precursor hairpin shaped double-stranded RNAs. miRNAs 
regulate expression of their target protein by binding to 3’-UTR of mRNA in 
sequence dependent manner. This binding either promotes target mRNA 
  
  
 
 
3 
degradation and/or inhibition of their translation. Since each miRNA can target 
hundreds of genes, they can play pivotal role in regulation of all cellular processes. 
(Mukherji et al., 2011; Ramalingam et al., 2014).  
miRNAs have been classified as either Intergenic miRNAs or intronic 
miRNA based on their location on the genome(Olena & Patton, 2010). Intergenic 
miRNAs possess independent promoter and are transcribed independently while 
intronic miRNAs are in the intron of a protein coding genes and most of the time 
share a promoter with its host gene. Most miRNAs are transcribed through RNA 
Pol II into 1000-2000bp long primary miRNA (pri-miRNA) with long stem loop 
structure. These pri-miRNAs are cleaved in to approximately 70-100 nucleotide 
long precursor microRNA (pre-miRNA) by RNAse III endonuclease Drosha. These 
pre-miRNAs are transported by mainly exportin-5. The pre-miRNAs are cleaved 
into mature 18-24 nucleotide long miRNA by RNAse III type enzyme Dicer. Dicer 
is highly specific enzyme which forms complex with two other proteins TRBP and 
PACT to form miRNA induced silencing (RISC) complex. RISC complex directly 
involve in RNA silencing process in which miRNA functions as a guide by base 
pairing with its target mRNAs, whereas AGO proteins function as effectors by 
recruiting factors that induce translational repression, mRNA deadenylation and 
mRNA decay. miRNA binding sites are usually located in 3’ untranslated region 
(UTR) of mRNAs. The 5’ end of miRNAs that spans from nucleotide position 2 to 
7 is critical for target recognition and has been given term ‘miRNA seed’. miRNAs 
are very crucial molecules since each miRNA targets hundreds of genes and 
majority of protein coding genes are miRNA targets. Thus, their expression is 
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tightly regulated and their dysregulation is often associated with various human 
disease including cancer and neurodevelopmental disorders (Bartel, 2004; H. Y. 
Lee & Doudna, 2012; Y. Lee et al., 2003; Shah & Chen, 2014). miRNA biogenesis 
has been demonstrated in figure 1.2. 
1.3 AUTOPHAGY AND CANCER 
Macroautophagy (referred to as autophagy now onwards) is a highly 
conserved process by which cells capture intracellular proteins, lipids and 
organelles, and deliver them to the lysosomal compartment for degradation (Fulda 
& Kogel, 2015). It is a complex process that involves more than 30 genes that 
regulates one of the three stages of the process namely Initiation, Elongation and 
Maturation. Core genes involved the process are known as ATG, an abbreviation 
of Autophagy related genes. During autophagy initiation pre-autophagosomal 
structures (PAS), also known as phagophore, elongate and fuse while engulfing a 
portion of cytoplasm within double-membraned vesicles, called autophagosomes. 
The autophagosomes first fuse with endosomes to form hybrid organelles called 
amphisomes that later fuse with acidic lysosomes where the entrapped cytosolic 
contents are degraded (Fig. 1.3). Final maturation stage of autophagy involves 
fusion of autophagosome and lysosome that give rise to “Autolysosome”.  
Key functions of autophagy are to provide energy and metabolic precursors 
under conditions of starvation and to alleviate stress by removal of damaged 
proteins and organelles, which are deleterious for cell survival. Therefore, 
autophagy appears to serve as a pro-survival stress response in most settings. 
However, its role in cancer seems to be complex and context-dependent as 
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evidences exist for its oncogenic as well as tumor suppressive role in cancer 
(Figure 1.4).  In tumor cells with defects in apoptosis, autophagy allows prolonged 
survival. Paradoxically, autophagy defects are associated with increased 
tumorigenesis, but the mechanism behind this has not been determined. Recent 
evidence suggests that autophagy provides a protective function to limit tumor 
necrosis and inflammation, and to mitigate genome damage in tumor cells in 
response to metabolic stress. So far, these data suggest that autophagy may limit 
tumor initiation by protecting cells from mutations while may function as oncogenic 
pathway by protecting cancer cell under metabolic stress frequently seen in 
established tumors.  
1.4 ESTROGEN RECEPTOR POSITIVE BREAST CANCER AND ENDOCRINE 
RESISTANCE 
17β-Estradiol or estrogen (referred as E2 hereafter), a steroid hormone that 
plays a significant role in mammary gland development, serves as one of the main 
risk factors for breast cancer development. In fact, approximately 75% of 
diagnosed breast tumors express estrogen receptor α (ERα). ERα is a ligand-
dependent transcription factor that, upon binding with E2, regulates genes involved 
in cell proliferation, differentiation, and migration. Therefore, deregulated actions 
of ERα signaling are associated with breast cancer development (Manavathi et al., 
2013).  
The ERα is a ligand-dependent transcription factor that belongs to the 
nuclear receptor superfamily of proteins with defined functional domains that can 
both activate and repress the expression of genes. In the absence of ligand, ERα 
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is sequestered in complex with an inhibitory heat shock protein in target cell nuclei. 
Upon ligand binding, the receptor detaches from the heat shock protein complex 
and undergoes dimerization(Klein-Hitpass, Schorpp, Wagner, & Ryffel, 1986). The 
interaction of ERα with target gene promoters can occur either directly, through 
specific estrogen response elements (ERE), or indirectly through contacts with 
other DNA-bound transcription factors such as activation protein 1, specificity 
protein (SP) 1, or NF-κB. Once tethered to DNA, the receptor can either positively 
or negatively regulate target gene transcription (O'Lone, Frith, Karlsson, & Hansen, 
2004). ERα regulates many genes that are involved in mammary gland 
development, and their altered expression is associated with breast cancer 
progression (Welboren, Sweep, Span, & Stunnenberg, 2009).  
 In addition to the classical genomic actions exerted by E2, E2 is also known 
to activate various growth factors through membrane-initiated steroid signaling 
(MISS). Figure 1.5 depicts various ER signaling pathways (Winter, Jung, Keller, 
Gregory, & Diederichs, 2009). Apart of genomic and non-genomic actions of estrogen 
on estrogen receptor, emerging studies suggest that posttranslational 
modifications, especially phosphorylation can also regulate function of estrogen 
receptor. Studies have shown that estrogen receptor can be activated in absence 
of ligand by MAPK, mTOR and AKT kinases. These kinases phosphorylate ERα 
at Ser 118 or Ser 167. Therefore, these kinases have been implicated in endocrine 
resistance to tamoxifen(Hayes & Lewis-Wambi, 2015). Due to several levels of 
complexity to the action of ERα in breast cancer cells, many patients receiving 
endocrine treatments develop resistance to therapy. Different molecular events 
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have been reported to cause resistance, such as ligand independent activation of 
ERα, overexpression of epidermal growth factor receptor or v-erb-b2 erythroblastic 
leukemia viral oncogene homolog 2 (ERBB2), over expression of co-activators 
such as NCOA3, FOXA1; and DNA methylation at the ERα promoter (6). Figure 
1.6 describes various mechanisms responsible for tamoxifen resistance(Hayes & 
Lewis-Wambi, 2015).  
1.5 MIRNAS IN CANCER THERAPEUTICS 
Approximately 2000 miRNAs have been identified in humans 
(www.mirbase.org). Despite their small number, they regulate 30% of all genes. 
Therefore, they play crucial role in almost all biological processes (Iorio et al., 
2005). miRNAs have been identified to play a crucial role in various human 
diseases, and therefore, they are interesting for drug discovery. One major 
limitation of novel drug discovery is drug target selection. Less than 1% of all 
approved drugs do not bind to proteins, whereas more than 80% of all drugs target 
only two protein classes: enzymes or receptors(Hopkins & Groom, 2002). 
Furthermore, not every protein can be targeted or modulated by a drug molecule. 
By contrast, intervention at the miRNA level may allow specific manipulation of 
every protein population: miRNA inhibitors induce selective upregulation of one 
protein population; by contrast, miRNA mimics induce gene silencing, thus 
resulting in downregulation of the target protein. Hence, miRNAs can be potential 
drug candidate for ‘undruggable’ proteins, enabling the cure of diseases, which, at 
present, seems impossible(Schmidt, 2014). Additionally, most drug molecules only 
target single molecule or a signaling pathway. Hence, such agents frequently face 
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resistance issues. Also, diseases such as cancers are known to possess cellular 
and molecular heterogeneity and therefore are notoriously known for resistance 
and relapse following chemotherapy. miRNAs due to their ability of targeting 
multiple pathways at same time offers another crucial advantage over traditional 
drug therapy. As a result, miRNAs are regarded as high-value drug targets. 
Several miRNA and RNAi based therapeutic are in fact currently under clinical 
trials. These agents are listed in Table 1(Chakraborty et al., 2017).  
1.6 GOALS OF THE PROJECT 
The overall goal of this project is to understand the role of miR-489 in breast 
cancer for the development of novel prognostic biomarker or therapeutic agent. 
Previously, we have established miR-489 as a tumor suppressor miRNA in breast 
cancer by targeting HER2 signaling pathway (Patel et al., 2016). Since then, 
several groups have demonstrated its tumor-suppressive role in many different 
cancers including gastric cancer, lung cancer, ovarian cancer, hepatic cancer, 
osteosarcoma, and bladder cancer (X. Chen et al., 2016; Kikkawa et al., 2010; J. 
Li et al., 2016; Wu et al., 2014; Yuan et al., 2017; Zhang et al., 2016). Remarkably, 
miR-489 has been reported to induce cell-cycle arrest and apoptosis, inhibit 
metastasis and epithelialto-mesenchymal transition in context-dependent manner. 
A thorough understanding of miR-489–mediated tumor suppression in a specific 
cancer will be valuable in evaluating the possibility of miRNA-489–based therapy. 
Hence, this study was aimed to identify novel pathways and molecular targets 
affected by miR-489, which will lead to better understanding of miR-489–mediated 
tumor suppression. 
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Figure 1.1: Breast cancer subtypes and their prevalence. Breast cancer is 
broadly classified in four subtypes based on surface receptor expression. Hormone 
positive breast cancer is most prevalent subtype with best prognosis and response 
to therapy. HER2-enriched cancer shows aggressive phenotype but respond well to 
HER2 targeted therapies while triple negative breast cancer tend to have the worst 
prognosis among all due to lack of specific target receptor or protein. This figure is 
adapted from breast cancer research foundation. 
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Figure 1.2: General mechanism of miRNA biogenesis. The canonical miRNA 
maturation includes the production of the primary miRNA transcript (pri-miRNA) by 
RNA polymerase II or III and cleavage of the pri-miRNA transcript (pri-miRNA) by 
Drosha-DGCR8 in the nucleus. The resulting pre-miRNA is exported by Exportin5-
RAN-GTP. In the cytoplasm, the RNase Dicer in complex with the double-stranded 
RNA-binding protein TRBP cleaves the pre-miRNA hairpin to mature length. The 
functional strand of the mature miRNA is loaded together with Argounaute (Ago2) 
proteins into the RNA-induced silencing complex (RISC) where it guides RISC to 
silence its target mRNAs through mRAN cleavage, translational repression or 
deadenylation. This figure has been adapted from (Peng & Croce, 2016) 
  
  
 
 
11 
 
  
Figure 1.3: Overview of mammalian autophagy pathway. Autophagy initiation 
begins with the formation of the phagophore assembly site (PAS). This is mediated 
by the UNC51-like kinase (ULK) complex, which consists of ULK1 (or ULK2), 
autophagy-related protein 13 (ATG13), Further nucleation requires the class III PI3K 
complex, which is composed of the vacuolar protein sorting 34 (VPS34) PI3K, along 
with its regulatory subunits ATG14L, VPS15 and beclin 1. Phagophore membrane 
elongation and autophagosome completion requires two ubiquitin-like conjugation 
pathways. The first produces the ATG5–ATG12 conjugate, which forms a multimeric 
complex with ATG16L, whereas the second results in the conjugation of 
phosphatidylethanolamine (PE) to LC3. PE-conjugated LC3 (LC3–PE) is required 
for the expansion of autophagic membranes, their ability to recognize autophagic 
cargoes and the fusion of autophagosomes with lysosomes. The resulting 
autophagosome fuses with lysosomal compartments, ultimately leading to formation 
of the autolysosome. This figure has been adapted from (Kaur & Debnath, 2015) 
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Figure 1.4: Role of autophagy in breast cancer.  This figure has been adapted 
from (Debnath, 2011). 
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Figure 1.5: Estrogen Receptor signaling pathways. The figure depicts various 
ER signaling pathways. Pathway A is called the classical genomic pathway, also 
known as Nuclear Initiated Steroid Signaling (NISS), where estrogen-ERα activates 
or repress transcription of estrogen response genes. Pathway B, the nonclassical 
genomic pathway, involves ER interactions with other transcription factors like AP-1, 
SP-1 or NFκB. Pathway C is E2-independent activation of ER through 
phosphorylation induced by growth factors such as MAPK, AKT, EGFR. Pathway D, 
known as Membrane Initiated Steroid Signaling (MISS), involves a small pool of 
membrane associated that, through recruitment of protein kinases (Src and PI3K), 
activate signaling cascades (Akt, MAPK). All these pathways converge to cell 
proliferation and survival.  This figure has been adapted from (Le Romancer et al., 
2011). 
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Figure 1.6: Mechanisms of Tamoxifen resistance. One of the mechanisms of 
tamoxifen (TAM) resistance involves loss of estrogen receptor (ER) alpha 
expression through epigenetic silencing of ESR1 gene. Tamoxifen-resistant growth 
is also stimulated by the upregulation of growth factor signaling pathways (HER2, 
IGFR1, and FGFR1) and subsequent activation of the mitogen-activated protein 
kinase (MAPK) cascade or phosphoinositide 3-kinase (PI3K) pathway. Finally, 
tamoxifen has even been shown to stimulate the growth of breast cancer cells when 
bound to certain coactivators, such as AIB1, and this is especially true in HER2-
expressing cells. This figure has been adapted from (Hayes & Lewis-Wambi, 2015). 
  
  
 
 
15 
 
 
 
  
 
 
Table 1.1: List of miRNAs under clinical trials or under development phase for 
prognostic marker or therapeutic agent. This figure has been adapted from 
(Chakraborty, Sharma, Sharma, Doss, & Lee, 2017) 
 
This table has been adapted from (Chakraborty, Sharma, Sharma, Doss, & Lee, 
2017) 
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CHAPTER 2 
MIR-489 REGULATES CELL VIABILITY AND CHEMO-
RESISTANCE BY INHIBITING AUTOPHAGY 
 
2.1 INTRODUCTION 
Breast cancer is a heterogeneous disease with several subtypes identified 
by presence or absence of surface receptors. Traditionally, breast cancer is 
classified in three major subtypes namely, Hormone positive, HER2 positive 
(HER2+) and Triple negative breast cancer (TNBC). (Heiser et al., 2012; Higgins 
& Baselga, 2011; Shah & Chen, 2014). Recent gene expression studies identified 
novel molecular signatures within the subtype suggesting patients with same 
subtype of breast cancer may show transcriptional and genomic heterogeneity and 
therefore may not respond similarly. Due to the discrepancies in transcriptional and 
genomic heterogeneity alnog with complex resistance mechanisms, the 
development of broad-range treatments has been restricted. Therefore, 
identification of a single therapeutic agent targeting multiple oncogenic and 
prosurvival pathways would provide a promising future cancer therapy. Since a 
single miRNA targets multiple pathways and controls gene expression of many1
                                                          
1 Soni M, Patel Y, Markoutsa E, Jie C, Liu S, Xu P, et al. Autophagy, Cell Viability and Chemo-
resistance are Regulated by miR-489 in Breast Cancer. Molecular cancer research: MCR 2018. 
Doi: 10.1158/1541-7786.MCR-17-0634. Reprinted here with permission from the publisher.      
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genes, they could offer considerable therapeutic options. miRNAs are small 
noncoding RNAs that posttranscriptionally regulate expression of their target 
genes. Because miRNAs regulate many genes, their dysregulation have been     
shown to cause various pathologic conditions including cancer. Identifying such 
dysregulated miRNAs and their targets might provide insights for the development 
of novel therapy.  
Autophagy has recently received great attention in the field of cancer and 
chemo-resistance due to its pro-survival role under stressful conditions.The role of 
autophagy in cancer remains controversial, as it exhibits tumor suppressive and 
tumor promoting activity in context and molecular subtype dependent manner. 
Studies have reported that autophagy protects cancer cells from metabolic stress 
such as starvation or hypoxia (Eskelinen, 2011). Due to its cytoprotective function 
it enables cancer cells to cope with cytotoxic or other stress induced by treatment. 
Indeed, autophagy inhibition has been shown to reverse resistance to several 
chemotherapeutic agents. Currently, chloroquine, an anti-malarial drug, is under 
clinical trials for adjuvant therapy to reduce resistance via autophagy inhibition in 
various cancers. Many miRNAs have also been shown to sensitize cancer cells to 
chemotherapy by inhibiting autophagy. For example, miR-200b has been shown 
to reverse autophagy mediated resistance to docetaxel by targeting ATG12 (Pan 
et al., 2015), while miR-140-5p disrupts cancer stem cell growth in colorectal 
cancer via autophagy inhibition (Wei, Cao, Deng, Su, & Cai, 2016; Zhai, Fesler, 
Ba, Wu, & Ju, 2015).  Understanding the role of miRNA in autophagy mediated 
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cancer cell survival and resistance may provide detailed insight on potential 
miRNA based therapies.  
In the present study, for the first time we reported that miR-489 inhibits 
autophagy by affecting multiple genes involved in the process. We further found 
that miR-489 reduces tumor cell survival and sensitizes tumor cells under 
metabolic stress induced by starvation via inhibiting autophagosome degradation. 
Moreover, we found that miR-489 can also sensitize breast cancer cells to 
doxorubicin via autophagy inhibition. From the combination of our in-vitro and in-
vivo studies, we report that miR-489 inhibits autophagy by targeting ULK1 and 
LAPTM4B and sensitizes tumor cells to doxorubicin by inhibiting doxorubicin 
induced cytoprotective autophagy and LAPTM4B expression. 
2.2 RESULTS  
2.2.1 IDENTIFICATION OF NOVEL PATHWAYS AND TARGETS REGULATED BY 
MIR-489 IN BREAST CANCER. 
Previously, we established that miR-489 functions as tumor suppressor 
miRNA in HER2+ breast cancer by directly inhibiting HER2 signaling pathway. To 
identify novel pathways regulated by miR-489, we first examined effect of miR-489 
on cell viability of 12 different breast cancer cell lines covering all three subtypes 
of breast cancer. Our MTT based cell viability assay showed that miR-489 
significantly reduces cell viability, although to different extent, in all three subtype 
of breast cancers (Fig. 2.1). Interestingly, some of the TNBC cell lines were much 
more sensitive to miR-489 compared to HER2+ cell lines. This result suggests 
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miR-489 targets other pathways involved in proliferation and survival besides the 
HER2 signaling pathway.  
To identify novel genes regulated by miR-489 in breast cancer, we 
conducted microarray analysis by transiently transfecting control scramble siRNA 
(scr) or miR-489 mimic (mimic) in T47D cell line (Fig. 2.2A). Our gene expression 
analysis also revealed multiple pathways affected by miR-489. We observed that 
several genes involved in autophagy were affected by forced expression of miR-
489 (Fig. 2.2B). We utilized target prediction tools such as miRwalk and 
TargetScan to identify potential miR-489 targets involved in autophagy. Consistent 
with our microarray data, target prediction tools also suggested multiple genes 
involved in regulation of autophagy such as ULK1, ATG4A, LAPTM4B, ATG4C, 
ATG2B, ATG3, ATG5, ATG7, ATG12 and ATG14 as potential target of miR-489. 
(Fig. 2.2C). Interestingly, miR-489 mediated cytotoxicity was associated with 
distinct morphological features, including the appearance of dense intracellular 
vacuolar structures (Fig. 2.3). This further indicated a possible perturbation of 
autophagy. To investigate effect of miR-489 on autophagy, we transfected breast 
cancer cell lines with non-targeting scramble miRNA (scr) miR-489 mimic (mimic) 
and miR-489 inhibitor (inh) and monitored the effect on autophagy marker LC3B 
using western blot. Conversion of non-lipidated soluble LC3B (LC3B-I) to 
phosphatidylethanolamine-conjugated LC3B (LC3B-II) serves as a sensitive 
indicator of autophagy (Klionsky et al., 2016). We found significant accumulation 
of LC3B-II upon miR-489 overexpression, while inhibition of miR-489 completely 
reversed this deposition (Fig. 2.4A-B).  
  
  
 
 
20 
We observed this effect in HER2 positive, estrogen positive and triple 
negative breast cancer cells suggesting autophagy modulation by miR-489 is 
independent of breast cancer subtype. In summary, we identified autophagy as a 
novel pathway modulated by miR-489 expression.  
2.2.2 MIR-489 INHIBITS AUTOPHAGY MAINLY BY BLOCKING MATURATION STEP 
 Autophagy is complex multistep process. Numerous assays have been 
developed to precisely decipher the effect on basal autophagy or autophagic flux. 
Although change in LC3B-I and II is an indicator of change in autophagy flux, it 
fails to provide conclusive information about autophagy activation or inhibition 
(Klionsky et al., 2016). Deposition of LC3B-II can be caused by induction of 
autophagosome (AP) formation or blockage of autophagosome degradation via 
fusion of autophagosome with lysosome (Autolysosome). To distinguish these two 
possibilities, we first used Bafilomycin A1 immunoblot. Bafilomycin A1 is a 
lysomotropic agent which inhibits the V-ATPase responsible for acidification of the 
lysosome, and prevents fusion of autophagosomes and lysosomes (Klionsky et al., 
2016). Comparison of LC3-II levels in the absence and presence of Bafilomycin 
A1 allows the effects of formation and degradation to be uncoupled. As shown in 
Figure 2.5A, 2.5B and 2.5C, no significant difference was detected between double 
treatment and lysomotropic agent alone at 48hrs and 72hrs time points, suggesting 
that miR-489 might be blocking degradation of autophagosome. Moreover, our 
finding on the clearance of cargo protein p62, another distinctive feature of 
autophagy, also indicated blockage of autophagosome degradation (Fig. 2.5D. 
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2.5E and 2.5F) (Klionsky et al., 2016; Mizushima, Yoshimori, & Levine, 2010). 
These results suggest that miR-489 inhibits autophagy by blocking formation of 
autophagosome and lysosome fusion (Autolysosome).  
We then asked whether autophagy inhibitors that block autophagosome 
formation such as 3-methyladenine (3-MA) or siATG5 can prevent miR-489 
induced autophagosome deposition. Consistent with previous observations, 3-MA 
and ATG5 knockdown indeed attenuated miR-489 induced p62 and LC3B-II 
deposition (Fig. 2.6A, 2.6B, 2.6C). Conversely, in conditions such as starvation 
that induces autophagosome synthesis, miR-489 restoration further increased 
LC3B-II and p62 deposition suggesting blockage at maturation step (Fig. 2.6D). 
Interestingly, this accumulation was comparable to that of Bafilomycin A1, which 
also blocks the fusion step. To further confirm that miR-489 inhibits formation of 
autolysosome (AL) by blocking fusion of autophagosome and lysosome, we used 
common dual fluorescent LC3B reporter, which  expresses an N-terminal fusion of 
mCherry and GFP to human LC3B (Klionsky et al., 2016). This reporter system 
enables real time monitoring of autophagic flux. Since, low pH quenches GFP 
fluorescence, AL is seen as distinct red aggregates, while AP appears as yellow 
aggregates due to overlap of red and green fluorescence. (Fig. 27A). If the 
autophagy pathway is in flux, then these yellow aggregates will be transient as 
APs fuse with acidic lysosomes to form ALs, in which the low pH quenches GFP 
fluorescence, resulting in rapid accumulation of dense red aggregates. However, 
blockage of autophagy at the fusion step results in accumulation of yellow puncta. 
Consistent with our earlier results, miR-489 mimic transfected cells show presence 
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of more yellow puncta compared to control, further suggesting miR-489 causes 
accumulation of AP by blocking fusion step (Fig. 2.7B, 2.7C). Together, these 
results indicate that miR-489 inhibits autophagy mainly by blocking the fusion of 
APs to lysosome.  
2.2.2 MIR-489 INHIBITS AUTOPHAGY BY DIRECTLY TARGETING ULK1 AND 
LAPTM4B 
Next, we seek to identify autophagy related genes that are directly targeted 
by miR-489. Our gene expression analysis along with target predication algorithm 
analysis revealed multiple genes as potential targets of miR-489 that are directly 
involved in autophagy pathway such as ATG4A, ULK1, ATG4C, LAPTM4B, 
EIG121, VMA21, WIPI1, ATP6V1C1 and EI24 (Fig. 2.2B). To validate our 
microarray results, we performed qRT-PCR after transient transfection of miR-489 
or control siRNA in indicated breast cancer cell lines (Fig. 2.8A). As shown in the 
figure, the expression of four out of six genes were greatly diminished upon miR-
489 reconstitution in multiple breast cancer cell lines. To further confirm, we 
performed western blot analysis and found downregulation of LAPTM4B and ULK1 
but not EI24 in all three cell lines (Fig. 2.8B). We were also interested in 
investigating whether knockdown of endogenous miR-489 would affect target 
genes expression. Indeed, miR-489 inhibitor efficiently increased the amounts of 
ULK1 and LAPTM4B (Fig. 2.8B). We then performed 3’UTR luciferase assay to 
identify direct targets. Our assay revealed that ULK1 (35% reduction, p-value = 
0.0184) and LAPTM4B (40% reduction, p-value = 0.0038) are direct target of miR-
489 while ATG4A might be an indirect target (Fig. 2.9A and 2.9B). Since, ULK1 
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and LAPTM4B are positive regulators of autophagy, these results further suggest 
that miR-489 negatively regulates autophagy. 
2.2.3 MIR-489 REDUCES TUMOR CELL SURVIVAL AND SENSITIZES TUMOR 
CELLS UNDER METABOLIC STRESS INDUCED BY STARVATION  
 
Since miR-489 inhibited autophagy, we seek to investigate contribution of 
autophagy inhibition in tumor suppressive effect of miR-489 and whether miR-489 
forced expression of miR-489 results in increased sensitivity of tumor cells to 
insults that induce autophagy as survival mechanism. Since starvation is a fairly 
common insult that requires autophagy for survival, we examined if miR-489 over 
expression can reduce tumor cell survival under starvation. We selected MDA-MB-
231 cells for this study as previous study has showed that MDA-MB-231 cells are 
more resistant to starvation compared to other breast cancer cell lines. Study also 
showed that this aggressive cell line is sensitive to autophagic induction and 
additionally possesses the ability to proliferate following nutrient deprivation (Y. I. 
Li et al., 2016). Consistent with this study we also observed that MDA-MB-231 cells 
were much more resistant to starvation compared to T47D and HCC1954 cells. 
We transfected MDA-MB-231 cells with scr, mimic or inh under complete media or 
starvation and performed cell survival assay at indicated time points. We found 
that miR-489 over expression significantly reduced survival under starvation (p-
value = 0.0001) (Fig. 2.10A and 2.10B). miR-489 over expression caused more 
than 20% growth inhibition after 72hrs of transfection under starvation compared 
to nutrient rich condition (Fig. 2.10C). Interestingly, this cytotoxic and cytostatic 
effect began as early as 24hrs under starvation. While this was not observed until 
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48hrs in nutrient rich medium. Consistent with previous observations, starvation 
indeed induce autophagy and miR-489 restoration showed stronger autophagy 
inhibition under starvation as indicated by increased accumulation of LC3B-II and 
p62 in western blot analysis (Fig. 2.10D). Western blot results also showed 
significant increase in cleaved caspase 3 upon miR-489 over expression under 
starvation. We also performed similar experiment on T47D and HCC1954 cells 
(Fig. 2.10A-F). Both cell lines were significantly affected under starvation (2.10B, 
2.10E). We tested whether miR-489 inhibition can protect these cells under stress 
induced by starvation. miR-489 inhibition marginally increased survival under 
starvation in HCC1954 (Fig. 2.11E, 2.11F). Interestingly, this protective effect was 
more prominent in T47D cells (Fig. 2.11B, 2.11C, p-value=0.0017) that possesses 
higher endogenous miR-489.   
2.2.4 AUTOPHAGOSOME ACCUMULATION BY MIR-489 IS PARTIALLY 
RESPONSIBLE FOR ITS TUMOR SUPPRESSIVE EFFECT.  
 
To examine whether cytotoxic effect of miR-489 is mediated through 
autophagy inhibition, we blocked autophagy at different stages using 
pharmacological and RNA interference approach under nutrient rich condition and 
under starvation and assessed effect of miR-489 on autophagic flux and cell 
viability. We observed that blocking early stages of autophagy by 3-MA or siATG5 
resulted in significant attenuation of cytotoxic effect of miR-489 (Fig. 2.12A-2.12D). 
This rescue effect was more pronounced under starvation. In fact, 3-MA and 
siATG5 treatment almost completely prevented miR-489 induced apoptosis as 
evidenced by western blot analysis of cleaved caspase 3 (Fig. 2.12C, 2.12D). 
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However, autophagy blockage at later stage by Bafilomycin A1 did not rescue cells 
from miR-489 induced death. Rather, it mildly synergized the growth inhibition (Fig. 
2.12A, 2.13B). These results suggest that increased autophagosome 
accumulation by miR-489 may account for its cytotoxic effect on these cells. 
Previous reports have shown that autophagosome accumulation confers 
cytotoxicity in cancer cells and blocking autophagosome synthesis by chemical 
inhibitor or by genetic ablation alleviates this cytotoxicity (Button, Roberts, Willis, 
Hanemann, & Luo, 2017; Choi, Jo, Lee, & Choi, 2011). Starvation is known to 
induce autophagosome formation. Hence, restoring miR-489 under starvation 
resulted in pronounced increase in autophagosome accumulation. This might 
explain why miR-489 further sensitized cells under starvation. We also observed 
greater rescue from miR-489 induced death under starvation upon blocking 
autophagosome synthesis by 3-MA or siATG5. Further confirming the idea that 
miR-489 induced autophagosome accumulation is crucial for its cytotoxic effect. 
Previous studies have also reported similar observations where perturbation of 
earlier stages of autophagy attenuated effect of autophagy inhibitors that block 
later stages (Geng, Kohli, Klocke, & Roth, 2010).    
In summary, these data suggest that miR-489 mediated autophagosome 
accumulation is at least partially responsible for its cytotoxic effect and it further 
sensitizes cancer cell death under metabolic stress induced by starvation due to 
further increase in autophagosome accumulation. 
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2.2.5 MIR-489 INHIBITS DOXORUBICIN INDUCED CYTOPROTECTIVE 
AUTOPHAGY AND SENSITIZES BREAST CANCER CELLS TO DOXORUBICIN 
 
Doxorubicin has been previously shown to induce cytoprotective autophagy 
(Chittaranjan et al., 2014; Kim et al., 2014). We examined autophagic flux upon 
miR-489 restoration in doxorubicin treated MDA-MB-231 and HCC1954 cells. 
Consistent with previous results, we found that doxorubicin indeed increased 
autophagic flux (Fig. 2.14A, 2.14B). This cytoprotective autophagy was blocked by 
miR-489 as indicated by increased LC3B-II levels. Previous studies have 
demonstrated that autophagy inhibition sensitizes breast cancer cells to 
doxorubicin (Chittaranjan et al., 2014; Kim et al., 2014; Zhou et al., 2015). 
We next tested whether miR-489 could sensitize breast cancer cells to 
certain front-line chemotherapeutic agents that have been shown to induce 
cytoprotective autophagy. Few studies have demonstrated that miR-489 is 
severely down regulated in cisplatin and doxorubicin resistant breast cancer cell 
lines and tumors (X. Chen et al., 2016; Wu et al., 2014). We hypothesized that 
restoring miR-489 can sensitize breast cancer cells to these chemotherapeutic 
agents. Using MTT based cell viability assay, we found miR-489 restoration 
sensitized MDA-MB-231, MDA-MB-468, HCC1954 and MDA-MB-453 to cisplatin 
and doxorubicin (Fig. 2.14C-2.14F). We observed substantial sensitization of 
doxorubicin upon miR-489 restoration, while only a mild sensitization effect was 
observed with cisplatin. Remarkably, double treatment of miR-489 and doxorubicin 
resulted in almost complete death of MDA-MB-231 and MDA-MB-453 cells (Fig. 
2.14C, 2.14D).  
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2.2.6 AUTOPHAGOSOME ACCUMULATION IS NECESSARY FOR MIR-489 
MEDIATED DOXORUBICIN SENSITIZATION 
 
Previous studies have demonstrated that autophagy inhibition sensitizes 
breast cancer cells to doxorubicin (Chittaranjan et al., 2014; Kim et al., 2014; Zhou 
et al., 2015). Consistent with these results, we observed sensitization with 
autophagy inhibitor Bafilomycin A1 and siATG5 (Fig. 2.15A, 2.15B). Several 
studies have demonstrated that autophagy inhibition at later stage is more effective 
in sensitizing tumor cells against chemotherapy (Kanematsu et al., 2010; C. Li et 
al., 2015; Shingu et al., 2009). Consistent with these results, we observed only 
mild sensitization with siATG5 while miR-489 and Bafilomycin A1 resulted in higher 
sensitization compared to siATG5. Interestingly, we observed greater sensitization 
with miR-489 compared to Bafilomycin A1. We then seek to examine role of 
autophagy in miR-489 mediated doxorubicin sensitization. Blocking autophagy at 
early step by siATG5 attenuated miR-489 induced drug sensitization (Fig. 2.15A) 
while blocking late stage autophagy by Bafilomycin A1 further showed mild 
sensitization at higher doxorubicin concentration (Fig. 2.15B). Furthermore, 
although ATG5 knockdown attenuated sensitization by miR-489, it failed to 
completely prevent this sensitization (see Fig. 5C, 0.5µM Dox. treatment).  These 
data suggest that miR-489 may also inhibit additional pathway besides autophagy 
that render cells resistant to doxorubicin. Apart from inducing autophagic flux, 
LAPTM4B has been shown to promote chemoresistance (de Ronde et al., 2013; 
L. Li et al., 2010; Y. Li et al., 2011; Y. Li et al., 2010).  Therefore, we seek to 
examine role of LAPTM4B in miR-489 mediated doxorubicin sensitization.  
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2.2.7 RESTORATION OF LAPTM4B ATTENUATES MIR-489 INDUCED 
AUTOPHAGY INHIBITION, APOPTOSIS AND DOXORUBICIN SENSITIZATION. 
 
To directly access role of LAPTM4B, we stably overexpressed LAPTM4B in 
MDA-MB-231 cell lines (Fig. 2.16A). As suggested by previous studies, LAPTM4B 
restoration increased autophagic flux and attenuated miR-489 induced autophagy 
inhibition (Fig. 2.16C). Surprisingly, LAPTM4B restoration increased survival by 
23% (p-value = 0.0005) upon miR-489 overexpression (Fig 2.16B). LAPTM4B 
overexpression not only rescued cells from miR-489 induced apoptosis but also 
increased survival by 17% (p-value = 0.0175) upon doxorubicin treatment and 33% 
(p-value = 0.001) upon combination treatment (Fig. 2.16D). To validate this result, 
we performed western blot analysis to monitor apoptotic marker cleaved caspase 
3 and detected significant reduction in cleaved caspase 3 in LAPTM4B 
overexpressing cell line (Fig. 2.16E). 
2.2.8 MIR-489 CAUSES DOXORUBICIN REDISTRIBUTION TO NUCLEUS  
 
LAPTM4B has been shown to sequester doxorubicin in lysosomes 
preventing their entry into nucleus thereby rendering it less effective (Y. Li, Iglehart, 
Richardson, & Wang, 2012; Y. Li et al., 2011; Y. Li et al., 2010; Meng et al., 2016). 
We tested whether miR-489 can induce redistribution of doxorubicin in MDA-MB-
231 cells and found that miR-489 indeed increased doxorubicin localization in 
nucleus (Fig. 2.17A, 2.17B and 2.17C). We then assessed effect of miR-489 on 
lysosomal integrity. We utilized Acridine orange dye which specifically stains 
lysosomal-endosomal organelles red. Our flow cytometry and confocal microscopy 
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results showed reduction in red fluorescence upon miR-489 restoration (Fig. 2.17D 
and 2.17E). These results indicate that miR-489 affects lysosomal integrity and 
that this may be one of the mechanism through which miR-489 sensitizes cell to 
doxorubicin. Collectively, these results indicate that miR-489 sensitizes MDA-MB-
231 cells to doxorubicin via inhibiting doxorubicin induced cytoprotective 
autophagy and through doxorubicin redistribution induced by LAPTM4B 
downregulation.  
2.2.9 RESTORATION OF ULK1 RESCUES CELLS FROM CYTOTOXIC EFFECT 
OF MIR-489 BUT NOT OF DOXORUBICIN  
 
We also examined role of ULK1 in miR-489 induced doxorubicin 
sensitization. ULK1 overexpression provided mild but significant rescue from the 
cytotoxic and cytostatic effect of miR-489 (Fig. 2.18A and 2.18B), but it could not 
rescue cells from doxorubicin (Fig. 2.18C). A modest rescue was observed in 
double treatment which may be due to rescue from the effect of miR-489. 
 2.2.10 MIR-489 SENSITIZES BREAST CANCER CELLS TO CHEMOTHERAPY IN-
VIVO 
Given the in-vitro findings and clinical significance, we tested whether miR-
489 could sensitize tumors to doxorubicin in-vivo. To explore the possibility of 
using miR-489 for therapy, we developed a nanoparticle delivery system to deliver 
miR-489 into tumor cells (Patel et al., 2016). In-vitro treatment with miR-489 
packaged nanoparticle inhibited target genes (Fig. 2.19A), indicating that 
nanoparticles can effectively deliver miR-489 into tumor cells. Consistent with our 
in-vitro data, miR-489 indeed sensitized cells to doxorubicin in-vivo (Fig. 2.19B). 
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Tumor growth in mice treated with doxorubicin alone was moderately reduced 
compared to control, while mice treated with miR-489 exhibited a significant 
reduction in tumor growth compared to control (p-value = 0.0441) and doxorubicin 
(p-value = 0.0284). Tumor growth in mice treated with the combination of 
doxorubicin and miR-489 was significantly reduced compared to control (by more 
than 75%; p-value = 0.0066), monotherapy with doxorubicin (by more than 40%; 
p-value<0.0001), or miR-489 alone (by more than 20%; p-value = 0.0326) (Fig. 
2.18B). Our qRT-PCR analysis on tumor samples confirmed down regulation of 
ULK1 and LAPTM4B mRNA (Fig. 2.19C). Our immunohistochemistry data 
revealed reduced cytoplasmic staining of LAPTM4B and significant reduction in 
number of Ki-67-positive cells in combination treatment when compared to the 
control tumors (Fig. 2.20A and 2.20B, p-value<0.0001). Western blot of tumor 
samples indicated autophagy inhibition and down-regulation of ULK1 and 
LAPTM4B (Fig. 2.20C). Together, these data demonstrated that miR-489 
delivered through nanoparticles inhibits tumor growth and sensitizes tumor cells to 
doxorubicin in xenografts. 
 
2.2.11 MIR-489 EXPRESSION IS INVERSELY CORRELATED WITH LAPTM4B 
IN PATIENT SAMPLES AND PREDICTS BETTER SURVIVAL IN 8Q22 AMPLIFIED 
BREAST CANCERS.   
 
To further define the clinical relevance of our findings, we examined miR-
489 and LAPTM4B expression in breast tissues from breast cancer patients 
(n=14). We found significant inverse correlation between expression of miR-489 
and LAPTM4B (Fig.2.21A). Similarly, in-silico analysis on primary tumors revealed 
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a strong inverse correlation between miR-489 and LAPTM4B expression with a p-
value of 0.0000413 (Fig. 2.21B).  
Considerable clinical evidences suggest that LAPTM4B over-expression 
promotes autophagy and chemoresistance (Y. Li et al., 2011; Y. Li et al., 2010). 
One study show that this over-expression is through amplification of the gene. The 
gene resides on 8q22 region, which is amplified in 20% of breast cancer patients 
(Y. Li et al., 2010). Therefore, we evaluated the clinical effect of the gene 
expression profiles of miR-489 in the patients with 8q22 gain/amplified tumor using 
a published data set containing 1302 breast cancer patients (Dvinge et al., 2013; 
Gray & Druker, 2012). Intriguingly, we found that 8q22 amplified patients with high 
miR-489 have a significantly better survival as compared to low miR-489 (p-value 
= 0.0005) (Fig. 2.21C). These results indicate potential application of miR-489 as 
prognostic biomarker in 8q22 amplified breast cancers.  
2.3 SUMMARY AND DISCUSSION 
In this study, we show that miR-489 inhibits autophagy in multiple subtypes 
of breast cancer cell line. Restoration of miR-489 reduces viability of MDA-MB-231 
under stress induced by starvation. Lastly, we show miR-489 can sensitize breast 
cancer cell lines to doxorubicin in-vitro and in-vivo. miR-489 imparts these 
phenotypic effects partly by directly targeting LAPTM4B and ULK1.  
  Our gene expression analysis reveals downregulation of many autophagy 
related genes upon miR-489 reconstitution. Although, we observe that miR-489 
affects multiple genes involved at different stages of autophagy, we conclude that 
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miR-489 restoration is mainly associated with defective maturation that leads to 
AP accumulation. The defect at this fusion step caused by miR-489 is supported 
by three independent experiment. First, miR-489 restoration leads to concomitant 
accumulation of LC3B-II and cargo protein p62. Upon completion of the autophagic 
process, p62 and LC3B-II are degraded via fusion with lysosome. However, 
blockage at maturation step prevents this degradation and results in simultaneous 
accumulation of both proteins. Second, no further significant accumulation of 
LC3B-II was observed in combination treatment of miR-489 and Bafilomycin A1. 
Last, miR-489 increases AP as shown by more yellow punta demonstrated by 
microscopic analysis of fluorescent mCherry-EGFP-LC3B reporter. Reduced 
ULK1 expression levels are commonly associated with decreased autophagic flux 
due to reduced autophagosome formation. In contrast to this notion, we observed 
accumulation of AP. However, it is worth to note that while ULK1 is involved in the 
initiation stage of the autophagy, it is not essential for activation of the LC3 
conjugation machinery. Studies show that ULK1 and ULK2 (homolog of ULK1) 
possess redundant roles in autophagy (Chan, Longatti, McKnight, & Tooze, 2009; 
Hara et al., 2008). and indeed, it takes a double knockout of Ulk1 and Ulk2 to 
completely block  amino acid starvation-induced autophagy in mouse embryonic 
fibroblasts (E. J. Lee & Tournier, 2011). This could be one of the reason why, 
despite ULK1 downregulation by miR-489, collective effect is observed at 
maturation stage.  LAPTM4B is a lysosomal transmembrane protein that has been 
shown to affect maturation of autophagosome. Studies show that knockdown of 
LAPTM4B results lysosomal membrane permeabilization (Blom et al., 2015) and 
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increases lysosomal pH which inhibits lysosome and autophagosome fusion (Y. Li 
et al., 2012). This results in accumulation of autophagosome with simultaneous 
deposition of LC3B-II and p62. Together, these results indicate that miR-489 
inhibits autophagy mainly through inhibiting autophagosome maturation.  
Autophagy has a contentious role in tumorigenesis. Loss of autophagy 
promotes oxidative stress, activation of the DNA damage response and genome 
instability which are known cause of cancer initiation and progression. (White, 
Mehnert, & Chan, 2015). However, autophagy has also been seen to promote 
tumor cell survival. Being a pro-survival mechanism, it allows cell survival under 
stressful conditions such as starvation and hypoxia. Due to excessive proliferation 
rate, these conditions are fairly common among tumors (Hu, Jahangiri, Delay, & 
Aghi, 2012). Autophagy, in such established tumors, promotes survival of cancer 
cells and inhibition of autophagy leads to tumor growth inhibition. Furthermore, 
genotoxic stress induced by various chemotherapeutic agents also induces 
cytoprotective autophagy. Several studies have reported that inhibiting autophagy 
in such cases leads to tumor growth inhibition and chemo-sensitization. However, 
impact of autophagy inhibition on tumor cell survival and chemo-sensitization 
depends on at which stage autophagy in blocked. Studies show that blocking 
autophagy at later stage have pronounced cytotoxic effect and sensitization. In 
fact, few studies suggested that blocking early stage autophagy might promote 
survival and attenuate effect of chemo-therapeutic agent. One such report 
explained that this contrasting response of autophagy inhibition at different stages 
is because this toxic effect is attributed to autophagosome accumulation (Button 
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et al., 2017). Since, inhibition of early stage of autophagy inhibits autophagosome 
synthesis, it alleviates cytotoxicity induced by autophagosome accumulation. 
Consistent with this result, blocking early stage of autophagy by 3-MA and siATG5 
blunted miR-489 induced cell death. These results suggest application of miR-489 
in tumors with increased autophagic flux or autophagy dependency. Few studies 
demonstrate higher basal autophagic flux and increased dependency of TNBC 
cells on autophagy for their survival (Maycotte et al., 2014).  Intriguingly, we 
observed significant cytotoxic effect of miR-489 in TNBC cells compared to cell 
lines of other breast cancer subtypes. TNBC cell line MDA-MB-231 is sensitive to 
autophagic induction and additionally possesses the ability to proliferate following 
nutrient deprivation (Y. I. Li et al., 2016). In the current study, we also observed 
MDA-MB-231 cells are more resistant to starvation compared to estrogen positive 
T47D cell line and HER2 positive HCC1954 cell line. miR-489 under these 
conditions can provide useful therapeutic approach to target such resistant and 
aggressive tumor cells. Interestingly, several groups including us, have shown that 
miR-489 is significantly down regulated in TNBC patients and cell lines, which 
might contribute to increased autophagic flux observed in this subtype (X. Chen et 
al., 2016; Patel et al., 2016). All these evidences suggest a notion that loss of miR-
489 in this subtype might play an important role for their survival. It will be 
interesting to explore if miR-489 mediated severe cytotoxic effect on these cells is 
specifically due to their increased sensitivity to autophagy inhibition or if miR-489 
shuts down other pro-tumorigenic pathways aberrantly overexpressed in this 
subtype.  
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miR-489 has long been reported in drug resistance. (X. Chen et al., 2016; 
Jiang et al., 2014; Miller et al., 2008; Wu et al., 2014). Various drug resistant cell 
lines, such doxorubicin resistant cell line, tamoxifen resistant cell line and cisplatin 
resistant cell line, display significantly reduced miR-489 expression. A study 
showed that MCF7/ADR cells have significantly higher basal autophagy level and 
inhibition of autophagy leads to sensitization of these resistant cells to 
doxorubicin(Guo, Tam, Santi, & Parissenti, 2016). Interestingly, restoration of miR-
489 leads to significant sensitization towards doxorubicin. A study reported that 
miR-489 sensitizes MCF7/ADR cells by inhibiting epithelial to mesenchymal 
transition (Borst et al.) through SMAD3 downregulation (Jiang et al., 2014). Several 
studies showed cells that underwent EMT require autophagy activation to survive 
during the metastatic spreading(Gugnoni, Sancisi, Manzotti, Gandolfi, & 
Ciarrocchi, 2016). Furthermore TGF-β, a master regulator of SMAD3 and EMT, 
has also been shown to induce autophagy and knockdown of SMAD3 attenuates 
TGF- β induced autophagy (Kiyono et al., 2009). However, on the other side 
autophagy has also been shown to contrast the activation of the EMT mainly by 
selectively destabilizing crucial mediators of this process (Gugnoni et al., 2016). It 
will be very interesting to explore cross talk between miR-489, autophagy and EMT 
to gain better understanding of miR-489’s role as therapeutic sensitizer. 
Restoration of miR-489 in some of these cell lines showed sensitization to 
specific chemotherapeutic agent (X. Chen et al., 2016; Jiang et al., 2014; Miller et 
al., 2008; Wu et al., 2014). Many mechanisms exist for drug resistance. The fact 
that miR-489 sensitizes cells to multiple chemotherapeutic agents indicates that 
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miR-489 regulates several pathways involved in drug resistance. One study 
showed miR-489 can sensitize doxorubicin resistant cell line via targeting SPIN1-
PI3K-Akt pathway (X. Chen et al., 2016). In the current study, we establish miR-
489-LAPTM4B-Autophagy pathway as an additional mechanism involved in 
doxorubicin resistance (Fig. 2.22). Our findings are consistent with previous 
studies that show role of LAPTM4B in increased autophagy and anthracycline 
resistance. Our clinical analysis found patient with 8q22 amplification, who have 
higher miR-489 expression, have better survival (p-value =0.0005) than patient 
with lower miR-489 expression. These data indicate potential clinical significance 
of miR-489 in 8q22 amplified patients, where it can mitigate effects of amplified 
LAPTM4B and sensitizes patients to doxorubicin. Together, these data suggest a 
possible application of using miR-489 as a potential biomarker or therapeutic 
sensitizer in a defined subgroup of resistant breast cancer patients.   
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Figure 2.1: Effect of miR-489 on cell viability of 12 different breast 
cancer cell lines representing all three major subtypes of breast 
cancer. MTT based cell viability assay showing relative survival of breast cancer 
cell lines after 72 hours post-transfection with scramble or mimic miR-489 ***, 
p<0.001; **, p<0.01; *, p<0.05. 
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Figure 2.2: Effect of miR-489 on expression of genes regulating 
autophagy. A. Experimental design. B Heatmap analysis of microarray data for the 
genes associated with autophagy. Genes were selected based on their differential 
expression between the scr-transfected cells and mimic-transfected cells. Red and 
blue indicate high and low gene expression, respectively. C. Hypergeometric 
analysis was performed using microarray data and putative targets identified using 
miRNA target–predicting software. 
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Figure 2.3: Demonstration of morphological changes in breast cancer 
cells after forced expression of miR-489.  Bright-field microscopy images of 
Scr- or Mimic-transfected cells. Arrow indicates intracellular endosomal, possibly 
vacuolar structures. Data are representative of three independent experiments. 72 
hours post-transfection with scramble or mimic miR-489 ***, p<0.001; **, p<0.01; *, 
p<0.05. 
Figure 2.4: Effect of miR-489 on autophagic flux. A. Indicated breast cancer 
cell lines were transfected with scr, mimic, or Inh. Protein was collected 72 hours 
post transfection and subject to western blot analysis of autophagy markers. GAPDH 
was used as a loading control. B. Quantification of LC3B-I and LC3B-II ratio. Data 
are representative of three independent experiments. 72 hours post-transfection with 
scramble or mimic miR-489 ***, p<0.001; **, p<0.01; *, p<0.05. 
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Figure 2.5: miR-489 inhibits autophagy by blocking autophagosome 
maturation. A-C Bafilomycin A1 blots after reconstituting cells with miR-489. T47D 
(A), MDA-MB-231 (B) and HCC1954 (C) cell lines were transfected with 28nM scr 
or mimic, for 48 or 72hrs and p62 and LC3B-II protein expression was assayed by 
western blot in presence or absence of Bafilomycin A1 (BafA1) (400nM). GAPDH 
was used as a loading control. D-F. Effect of miR-489 on clearance of p62 and 
LC3B-II deposition. T47D (D), MDA-MB-231 (E) and HCC1954 (F) cell lines were 
transfected with 28nM scr, mimic or inhibitor for 72hrs and p62 and LC3B-II protein 
expression was assayed by western blot.  
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 Figure 2.6: Effect of autophagy inducers or inhibitors on miR-489 
induced autophagy inhibition.  A Schematic diagram showing mechanism of 
action and effect of each autophagy modulator. B Western blot analysis of 
autophagic flux after forced expression of miR-489 in presence or absence of 3-MA 
and siATG5 (C). Cells were transfected with 28nM scr or mimic, for 24hrs, and then 
treated with 3-MA for 48hrs. Autophagic flux was then analyzed using western blot. 
GAPDH was used as a loading control. D Starvation increases LC3B-II and p62 
deposition by miR-489. Autophagic flux was assessed after forced expression of 
miR-489 with or without serum by western blot.  
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Figure 2.7: miR-489 inhibits autophagy by blocking autophagosome and 
lysosome fusion. A. Schematic diagram of mCherry-EGFP-LC3B reporter. B. 
Confocal microscopy of autophagy maturation.  MDA-MB-231 cells stably 
expressing mCherry-EGFP-LC3B fusion protein were transfected with 28nM scr or 
mimic for 48hrs or Bafilomycin for 4hrs and assayed for co-localization of red and 
green punta using confocal microscopy. C. Quantitative analysis of red and yellow 
punta in MDA-MB-231 cells at 48hrs post-transfection of scr or mimic ***, p<0.001; 
**, p<0.01; *, p<0.05. 
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Figure 2.8: miR-489 inhibits autophagy by inhibiting multiple genes 
involved in the process. A MDA-MB-231 and T47D cell lines were transfected 
with 28nM scr or mimic. RNA was isolated 72hrs post transfection and qRT-PCR 
was performed to examine expression level of indicated genes. Data are means of 
three replicates + SEM. B. Western blot showing expression of potential targets 
upon transfection of 28nM scr, mimic or inh in indicated cell lines. GAPDH was used 
as a loading control. ***, p<0.001; **, p<0.01; *, p<0.05. 
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Figure 2.9: LAPTM4B and ULK1 are direct targets of miR-489. A 
Schematic representation of the target mRNA with putative miR-489 binding site in 
the 3’ UTR by S fold database, where the seed region is highlighted in red. B 
HEK293T cells were co-transfected with miR-489 expressing vector or empty vector 
and renilla expressing vector for 72hrs. Firefly luciferase was measured for each 
condition and normalized with renilla luciferase. Normalized luciferase activity was 
compared with WT-3’UTR and Mutant 3’ UTR of target mRNA. Data are means of 
three replicates + SEM. ***, p<0.001; **, p<0.01; *, p<0.05. 
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Figure 2.10: miR-489 reduces tumor cell survival and sensitizes tumor 
cells under metabolic stress induced by starvation via autophagy 
inhibition. MDA-MB-231 cells were transfected with 28nM scr, mimic or inh in 
complete media (A) or low serum (B). Cell viability assay was performed at indicated 
time points (0, 24, 28 and 72hrs) using MTT. *, p < 0.05; **, p < 0.01; ***, p < 0.001. 
Data are means of three replicates + SEM. C. Relative inhibition by mimic under 
both conditions at indicated time points. D. MDA-MB-231 cells were transfected with 
28nM scr, mimic or inh in complete media or low serum for 72hrs and western blot 
was performed to investigate expression of cleaved caspase 3 and autophagy 
markers. GAPDH was used as a loading control. Data are means of three replicates 
+ SEM. ***, p<0.001; **, p<0.01; *, p<0.05. 
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Figure 2.11 Inhibition of endogenous miR-489 imparts resistance to 
starvation-sensitive cell lines. T47D (A-C.) and HCC1954 (D-F.) were 
transfected with 28nM scr or mimic under complete media or low serum condition. 
Cell viability was measured at indicated time point using MTT assay. *, p < 0.05; **, 
p < 0.01; ***, p < 0.001. Data are means of three replicates + SEM. 
 
  
  
 
 
47 
 
 
 
 
 
 
Figure 2.12 Blocking early stage of autophagy attenuates cytotoxic 
effect of miR-489. MDA-MB-231 cells were transfected with 9.3nM scr or mimic in 
complete media or low serum in presence or absence of 3-MA (5mM) or siATG5 
(50nM) treatment and cell viability assay (A,B) and western blot analysis (C,D) was 
performed to examine autophagic flux and apoptosis *, p < 0.05; **, p < 0.01; ***, p < 
0.001. Data are means of three replicates + SEM.  
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Figure 2.13: Blocking late stage of autophagy fails to protect cells from 
cytotoxic effect of miR-489. MDA-MB-231 cells were transfected with 9.3nM scr 
or mimic in complete media or low serum in presence or absence of BafA1 (50nM) 
and cell viability assay (A) and western blot analysis (B) was performed to examine 
autophagic flux and apoptosis *, p < 0.05; **, p < 0.01; ***, p < 0.001. Data are 
means of three replicates + SEM.  
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Figure 2.14 Forced expression of miR-489 inhibits doxorubicin induced 
cytoprotective autophagy and sensitizes cells to doxorubicin. A-B. MDA-
MB-231 and HCC1954 cells were transfected with scr or mimic for 72hrs in absence 
or presence of doxorubicin and autophagy marker LC3B-I and LC3B-II were 
monitored to examine autophagic flux. C-F. Indicated breast cancer cell lines were 
transfected with 28nM scr or mimic for 72hrs in presence of doxorubicin (0.75µM) for 
48hrs and cell proliferation was measured by MTT assay. Data are representative of 
three independent experiments. *, p < 0.05; **, p < 0.01; ***, p < 0.001. 
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Figure 2.15: Blocking early stage but not late stage autophagy prevents 
miR-489 mediated doxorubicin sensitization.  A. MDA-MB-231 cells were 
transfected with 9.3nM scr or mimic with or without siATG5 for 24hrs and treated 
with indicated concentration of doxorubicin for 48hrs and cell proliferation was 
measured by MTT assay. B. MDA-MB-231 cells were transfected with 9.3nM scr or 
mimic with for 24hrs and treated with indicated concentration of doxorubicin in 
presence or absence of Bafilomycin A1 (50nM) for 48hrs and cell proliferation was 
measured by MTT assay. Data are representative of three independent experiments. 
*, p < 0.05; **, p < 0.01; ***, p < 0.001. 
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Figure 2.16: LAPTM4B restoration attenuates tumor suppressive effect 
of miR-489 and prevents miR-489 induced doxorubicin sensitization. A. 
Western blot indicating stable over expressing LAPTM4B. GAPDH was used as a 
loading control for western blot analysis. B-C. MDA-MB-231 cells stably expressing 
LAPTM4B were transfected with 28nM scr or mimic. Cell viability assay (B.) and 
western blot (C.) was performed 72hrs post transfection to examine autophagic flux 
and apoptosis. D-E. MDA-MB-231 cells stably expressing LAPTM4B were 
transfected with 28nM scr or mimic with or without doxorubicin followed by cell 
viability assay (D.) and western blot analysis (E.) 
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Figure 2.17: Forced expression of miR-489 causes doxorubicin 
redistribution to nucleus. A. Microscopy analysis of subcellular localization of 
doxorubicin. Confocal microscopy was performed 72hrs after MDA-MB-231 cells 
were treated with 28nM scr or mimic with doxorubicin. Data are means of three 
replicates + SEM. Data are representative of three independent experiments. B. 
Quantification of cells with nuclear localization of doxorubicin. C. Microscopy 
analysis of subcellular localization of doxorubicin. Confocal microscopy was 
performed 72hrs after NCI/ADR-Res cells were treated with 28nM scr or mimic with 
doxorubicin.  D. MDA-MB-231 cells were transfected with 28nM scr or mimic and 
stained with Acridine orange (1mg/ml) for 20min and flow cytometry was performed 
to examine lysosomal integrity. E. Confocal microscopy of MDA-MB-231 cells after 
transfection with scr or mimic and staining with Acridine orange (1mug/ml) for 20min. 
Data are representative of three independent experiments. 
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Figure 2.18: ULK1 restoration rescues MDA-MB-231 cells from cytotoxic 
effect of miR-489 but not from doxorubicin. A-B. MDA-MB-231-ULK1 
overexpressing stable cells and vector cells were transfected with scr or mimic for 
72hrs followed by (A.) western blot analysis and (B.) MTT assay C.  MDA-MB-231 
cells stably expressing ULK1 and vector cells were transfected with 28nM scr or 
mimic with or without doxorubicin and cell viability was measured 72hrs post 
transfection. Data are representative of three independent experiments. *, p < 0.05; 
**, p < 0.01; ***, p < 0.001. 
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Figure 2.19: Nanoparticle-delivered miR-489 inhibits tumor growth and 
sensitized cells against doxorubicin in vivo. A. In-vitro characterization of 
nanoparticles delivering miR-489. MDA-MB-231 and MCF7 cells were treated with 
control and miR-489 loaded particles for 72 hours. Western blot indicates successful 
delivery of microRNA as indicated by downregulation of targets. B. miR-489 inhibits 
tumor growth and sensitized cells against doxorubicin in xenograft animals. After the 
tumors were palpable, the animals were randomly assigned into four groups (n=5 
per group). All animals were injected with miR-489 or control encapsulated in 
nanoparticle every third day. The treatment starting day was referred to as ‘Day 
zero’ in the figure.  Expression of miR-489 and its targets in tumors. RT-PCR was 
performed on the xenograft tumors samples to measure expression levels of miR-
489, ULK1 and LAPTM4B. C. Successful delivery of miR-489 via nanoparticles in 
tumors. Graph shows relative miR-489 expression (log10 (fold change)) in control or 
miR-489 loaded nanoparticles and Relative expression of ULK1 and LAPTM4Bin 
tumors samples. 
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Figure 2.20: Demonstration of tumor growth reduction, doxorubicin 
sensitization and autophagy inhibition by miR-489 using IHC and 
western blot analysis. A. IHC analysis revealed reduced expression of 
LAPTM4B and Ki67 in tumors treated with miR-489 encapsulated nanoparticles. B. 
Quantification of Ki-67 positive cells in tumors of all four groups. C. Western blot 
analysis of tumors revealed down regulation of ULK1, LAPTM4B and autophagy 
inhibition by miR-489. GAPDH was used as a loading control. 
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Figure 2.21: Correlation of miR-489 expression with LAPTM4B 
expression and 8q22 amplification in breast cancer patients. A. miR-489 
and LAPTM4B expression was measured in breast tissues form breast cancer 
patients (n=14) using qPCR. B. Correlation of miR-489 and its potential target gene 
expression in primary breast cancers. The linear dependence between miR489 and 
its potential target genes expression was evaluated by Pearson analysis of a 
published breast cancer data set. C. miR-489 expression predict overall survival of 
breast cancer patients with 8q22 gain/amplified tumors. Patient survival was 
estimated using the Kaplan-Meier method and compared with log-rank tests. The Y 
axis represents the probability of overall survival. *, p < 0.05; **, p < 0.01; ***, p < 
0.001.  
 
  
  
 
 
57 
 
  
 
 
 
 
 
 
 
Figure 2.22: Proposed working model depicting role of miR-489 in 
regulation of autophagy, cell viability and chemo-resistance. Starvation 
and chemotherapy induced genotoxic stress induces cytoprotective autophagy and 
increases autophagosome formation and maturation. miR-489, by targeting ULK1 
and LAPTM4B, inhibits autophagosome maturation and causes autophagosome 
accumulation which leads to cell death. miR-489 also causes doxorubicin 
redistribution to nucleus by inhibiting LAPTM4B and further prevents LAPTM4B 
mediated autophagy induction and resistance to metabolic stress.  
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CHAPTER 3 
THE ROLE OF MIR-489 IN HORMONE POSITIVE BREAST CANCER 
AND TAMOXIFEN RESISTANCE 
3.1 INTRODUCTION 
Oncogenic activation of the estrogen receptor (ER) signaling pathway 
occurs in over 70% of breast cancers. Although, this subtype of breast cancer has 
best prognosis due to targeted endocrine therapies, most patients with advanced 
disease eventually develop resistance to these endocrine therapies, and even for 
patients treated in the adjuvant setting, there is a consistent risk of relapse that 
persists indefinitely (Nass & Kalinski, 2015). Furthermore, approximate 50% of 
patients with locally advanced or metastatic ER+ breast cancer do not respond to 
first-line endocrine treatment (Clarke, Tyson, & Dixon, 2015). Besides, most 
patients who initially respond to the therapy eventually develop secondary 
acquired resistance. Despite significant research efforts and discoveries made in 
recent years, the precise reasons for endocrine therapy failure in patients with ER+ 
breast cancer remain largely unknown. Published studies have implicated 
mutations in the ESR1 gene; epigenetic silencing of ESR1, activated growth factor 
receptor signaling, including EGFR/HER2 pathway, PI3K-AKT pathway and MAPK 
pathway and over expression of co-activators such as NCOA3, FOXA1, as 
important mechanisms of 
  
  
 
 
59 
de novo or acquired resistance (Fan, Maximov, Curpan, Abderrahman, & Jordan, 
2015; Jeselsohn, Buchwalter, De Angelis, Brown, & Schiff, 2015; Osborne & Schiff, 
2011). This has led to various targeted combination strategies aiming to combat 
endocrine resistance. 
Downregulation of miR-489 has been observed in tamoxifen-resistant 
breast cancer (Rugo et al., 2016) but its functional involvement remains 
unexplored. In this study, we systematically investigated the functional roles of 
estrogen-regulated miR-489 in ER+ breast cancer. We demonstrated that 
downregulated miR-489 expression promotes aggressiveness, estrogen-
independent growth and acquired tamoxifen resistance of ER+ breast cancer cells. 
Thus, patients with ERα breast cancer with low miR-489 expression may represent 
a subpopulation that is intrinsically resistant to endocrine therapies. 
3.2 RESULTS 
3.2.1 MIR-489 EXPRESSION IS POSITIVELY CORRELATED WITH ESTROGEN 
RECEPTOR IN CELL LINES AND PATIENT SAMPLES. 
 
Previously, we and several other labs have demonstrated that miR-489 is a 
tumor suppressor miRNA and is lost in mammary tumorigenesis (Patel et al., 2016; 
Soni et al., 2018). However, not much is known about the regulation of miR-489 in 
breast cancer. Our analysis of miR-489 expression in 13 different breast cancer 
cell lines suggest that it is highly expressed in hormone positive luminal breast 
cancer cell lines (Fig 3.1A). Interestingly, miR-489 along with its host gene CALCR 
is positively correlated with estrogen receptor and its responsive genes such as 
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PGR and TFF1 expression in clinical samples (Fig. 3.1B). Furthermore, we have 
observed that miR-489 is highly expressed in luminal cells compared to basal cells 
(Figure 3.1C). All these evidences suggest that miR-489 may be an estrogen 
and/or progesterone regulated miRNA.  
3.2.2 E2-ERΑ AXIS REGULATES EXPRESSION OF MIR-489. 
 
To investigate potential role of estrogen in regulation of miR-489 
expression, we examined expression level of miR-489 and its host gene CALCR 
upon estrogen and progesterone stimulation and compared with unstimulated 
(vehicle treated) cells at different time points in T47D cell lines. We choose T47D 
cell line as it also expresses functional progesterone receptor and does not require 
pre-treatment of estrogen to induce progesterone receptor (Cittelly et al., 2013). 
We observed upregulation of known estrogen responsive genes such as PGR, 
CXCL12, GREB1 and NRIP1 upon estrogen stimulation and induction of known 
progesterone responsive gene, EZF upon progesterone stimulation. (Figure 3.2A, 
3.2B). Interestingly, we also observed significant upregulation of miR-489 and 
CALCR in upon estrogen treatment but did not see significant upregulation upon 
progesterone treatment (Figure 3.2C, 3.2D). We performed similar experiment in 
two other ER+ breast cancer cell lines MCF7 and BT474. Stimulation with estrogen 
resulted in significant increase in miR-489 and CALCR expression (Figure 3.2E, 
3.2F). Interestingly co-treatment of estrogen and progesterone showed smaller 
increase, suggesting progesterone reduced induction miR-489 and CALCR 
expression by estrogen. This result is consistent with previous study that showed 
progesterone represses some of estrogen regulated genes by affecting estrogen 
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receptor transcription assembly (Mohammed et al., 2015). To further confirm these 
results, we examined miR-489 and CALCR expression level upon estrogen 
depletion. As expected, depletion of estrogen significantly reduced the expression 
of known estrogen responsive genes along with miR-489 and CALCR in all three 
cell lines tested (Figure 3.3). These results are consistent with several studies that 
reported modulation of miR-489 upon estrogen depletion or stimulation (Baran-
Gale, Purvis, & Sethupathy, 2016, Bailey, 2015). Interestingly, we observe that 
CALCR upregulation reached its peak at 24 hours in T47D while it peaked at 
72hours for miR-489. We also observed stronger induction of CALCR mRNA 
compared to miR-489. This suggest that estrogen treatment alters the ratio of miR-
489 and CALCR mRNA and that estrogen may affect processing or maturation of 
miR-489. However, further experiments are needed to test this notion. In summary, 
these data suggest that miR-489 is an estrogen regulated miRNA in breast cancer. 
3.2.3 MIR-489 ACTS AS A NEGATIVE FEEDBACK TO CONFINE ESTROGEN 
INDUCED PROLIFERATION IN BREAST CANCER 
 
Since, miR-489 expression is ERα regulated, we inspected if miR-489 
regulates estrogen responsiveness of ERα breast cancer cells. Previously, we 
have observed that miR-489 inhibits proliferation of all breast cancer cell lines 
including ERα+ cell lines (Patel et al., 2016; Soni et al., 2018). We performed cell 
viability assay using several ER+ cell lines and found that forced expression of 
miR-489 resulted in a significant decrease, while the inhibition of miR-489 led to a 
significant increase in total cell viability in all cell line tested (Figure 3.4A). 
Therefore, we seek to examine role of miR-489 in estrogen induced proliferation. 
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For functional studies, the effects of forced expression or inhibition of miR-489 
were examined in presence of estrogen. The forced expression of miR-489 
resulted in a significant decrease, while the inhibition of miR-489 led to a significant 
increase in total cell viability of MCF-7 and T47D cells over 6 days (Figure 3.4B, 
3.4C). Inhibition of miR-489 increased growth by 2-fold in MCF7 cells and 3.5-fold 
in T47D cells (Figure 3.4D, 3.4E). As expected, estrogen treatment significantly 
increased colony formation ability of both MCF7 and T47D cells (Figure 3.4F). 
Forced expression of miR-489 almost completely inhibited estrogen induced 
colony formation of both cells. Interestingly, inhibition of endogenous miR-489 
drastically enhanced estrogen mediated colony formation. These results suggest 
that miR-489 may also affect cancer stem like cells or progenitor cell population. 
We then examined effect of miR-489 on cancer stem like cells by flow cytometry 
using CD24 and CD44 surface markers and by performing mammosphere forming 
efficiency (Balvers et al, 2015.). Consistent with previous results, we observed that 
estrogen increased cancer stem like cell population (CD24low CD44high) by 3-fold 
in MCF7 cells (Figure 3.5A, 3.5B) and 10-fold in T47D cells (Figure 3.5C, 3.5D) 
(Fillmore et al., 2010). As observed in clonogenic assay, inhibition of endogenous 
miR-489 further increased cancer stem like cell population by more than 3-fold in 
MCF7 cells and by more than 11-fold in T47D cells. Similarly, we also observed 
increased mammosphere forming efficiency (MFE) upon estrogen treatment and 
miR-489 inhibition not only increased MFE but also increased mammosphere size 
(Figure 3.6A, 3.6B, 3.6C, 3.6D). As observed in colony formation assay, forced 
expression of miR-489 almost completely prevented mammosphere formation.  
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Together, these results suggest that estrogen regulated miR-489 acts as a 
negative feedback to confine estrogen induced tumor cell growth and loss of miR-
489 may promote uncontrolled growth of ER+ breast cancers. This may explain 
why ER+ breast cancers with low mir-489 are more aggressive.  
3.2.4 MIR-489 INHIBITS ESTROGEN SIGNALING IN ER POSITIVE BREAST 
CANCER CELLS  
 
Reconstitution of miR-489 in ER-positive cells reduced their proliferation 
raised the possibility that miR-489 may inhibit ER signaling. To test this hypothesis, 
we measured estrogen receptor activity in T47D-ERE-Luc reporter cell line. As 
expected, we observed inhibition of estrogen receptor activity upon miR-489 over 
expression and increased activity by inhibiting endogenous miR-489 (Figure 3.7A). 
We also confirmed this effect in MCF7 cell line by transiently transfecting ERE-Luc 
reporter plasmid and found similar result (Figure 3.7B). Our gene expression 
analysis on T47D further supported this results as miR-489 restoration 
downregulated known estrogen responsive genes (Figure 3.7C). We then 
validated microarray results by performing qRT-PCR analysis on Estrogen 
receptor positive and negative cell lines. Interestingly, miR-489 caused down 
regulation of estrogen responsive genes only in estrogen receptor positive cell 
lines (Figure 3.8A) but did not affect or in some instances increased the expression 
of these genes in ER-ve cell lines (Figure 3.8B). These results suggest that miR-
489 does not directly target these genes but modulate their expression by inhibiting 
estrogen signaling. In summary, it seems that miR-489 may act as an endogenous 
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negative feedback loop to regulate estrogen induced gene expression in estrogen 
receptor positive breast cancer.   
3.2.5 MIR-489 INHIBITS ESTROGEN RECEPTOR NUCLEAR LOCALIZATION BY 
DIRECTLY TARGETING P38 MAPK 
 
We then sought to elucidate molecular mechanism responsible for miR-489 
mediated inhibition of Estrogen-ERα axis. Multiple mechanisms have been 
identified that regulate Estrogen-ERα mediated gene expression. Direct inhibition 
of ERα or its co-factors, inhibition of kinases that activates ERα or inhibition of 
estrogen induced nuclear localization of ERα have been previously reported to 
regulate estrogen induced gene transcription (Manavathi et al., 2013). We 
examined if miR-489 exerts its effects by affecting localization of estrogen 
receptor. Interestingly, forced expression of miR-489 almost completely reversed 
localization of estrogen receptor from nucleus to cytoplasm in MCF7 and T47D cell 
lines (Figure 3.9A, 3.9B). Conversely, inhibition of endogenous miR-489 
significantly increased nuclear localization. Majority of MCF7 cells showed 
significant localization of ERα into nucleus while T47D showed some cytoplasmic 
ER as well. Many factors have been reported to regulate localization of estrogen 
receptor. Importins and exportins have been shown to regulate nuclear import and 
export respectively. HSP90 and HSP70 binds to ER alpha and are responsible for 
its cytoplasmic retention. Various post-translational modifications including 
phosphorylation have also been shown to regulate estrogen localization. We then 
looked target prediction tools to find potential miR-489 target responsible for 
regulation of ERα nuclear transport. We found Importinα 7 and p38 MAPK (H. Lee 
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& Bai, 2002) as potential miR-489 target which has been previously shown to 
regulate nuclear localization. However, our western blot results do not show any 
change in Importinα 7 expression upon miR-489 over-expression or inhibition. 
Interestingly, forced expression of miR-489 significantly downregulated 
phosphorylated p38 MAPK and total p38 MAPK (Figure 3.10A). We then 
performed 3’UTR assay to examine if p38 MAPK is a direct target of miR-489. 
Forced expression of miR-489 significantly reduced luciferase activity of wild type 
construct while it did not affect luciferase activity of construct with mutant miR-489 
binding site (Figure 3.10B).  This result confirms that p38 MAPK is a direct target 
of miR-489. 
Next, we examined effect of p38 MAPK inhibition SB203580 on estrogen 
receptor localization. We transfected control siRNA or miR-489 mimic for 72hrs or 
treated with DMSO or 10uM SB203580 for 24hrs in hormone starved cells followed 
by treatment with estrogen to examine estrogen induced nuclear localization of 
estrogen receptor. Cell treated with miR-489 showed cytoplasmic localization of 
ER. Similarly, cells treated with p38 MAPK inhibitor phenocopied effect of miR-489 
on ER localization in both cell line tested (Figure 3.11A, 3.11B). Our data suggest 
that p38 MAPK activation is necessary for nuclear translocation of ERα. Therefore, 
we tested if estrogen activates p38 MAPK which in turn then mediates nuclear 
translocation. Since, estrogen induced ERα nuclear translocation occurs within 5-
30 minutes, we performed time course of estrogen treatment on MCF7 and T47D 
cell lines. We observed sharp increase in phospho-p38 MAPK and its downstream 
target phosphor-ATF2 upon estrogen treatment in both cell lines (Figure 3.12A, 
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3.12B). These results are consistent with previous studies that showed estrogen 
mediated activation of p38 MAPK in various tissues (H. Lee & Bai, 2002; Seval, 
Cakmak, Kayisli, & Arici, 2006). This suggest an evidence of positive feedback 
loop between E2-ERα axis and p38 MAPK in mammary cells. Binding of E2 leads 
to activation of p38 MAPK and activation of p38 MAPK leads to nuclear 
translocation of ERα which is necessary for its function as transcription factor 
(Figure 3.12C).  
3.2.6 MIR-489 INHIBITS ESTROGEN RECEPTOR PHOSPHORYLATION BY 
INHIBITING MAPK AND PI3K-AKT PATHWAY 
 
Previous studies have shown phosphorylation of ERα at Serine 118 and 
Serine 167 is necessary for its activity as transcription factor. MAPK and AKT are 
two major kinases that regulates phosphorylation at Ser 118 and Ser 167 sites 
respectively (Anbalagan & Rowan, 2015). In our previous study we reported that 
miR-489 inhibits MAPK and PI3K-AKT pathway. Therefore, we examined effect of 
miR-489 on estrogen receptor phosphorylation at these sites. As expected, forced 
expression of miR-489 dramatically reduced phosphorylation of ERα at both 
phosphorylation sites (Fig 3.13A, 3.13B). We then examined effect of inhibitors of 
MAPK (U0126), PI3K-AKT (LY294002) and p38 MAPK (SB203580) on estrogen 
signaling and estrogen induced growth. Consistent with previous studies, we 
noticed reduction in transcription activity of estrogen in presence of these inhibitors 
as shown by ERE-Luc reporter assay (Fig. 3.14A). We further confirmed this result 
by examining expression of known estrogen responsive genes and again found 
attenuation of estrogen mediated upregulation of these genes (Fig. 3.14B). We 
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also confirmed effect of inhibitors by measuring their effect on estrogen induced 
proliferation and noticed significant reduction in proliferation (Fig 3.14C and 
3.14D). Additionally, these inhibitors also attenuated enhanced proliferation upon 
miR-489 inhibition (Fig. 3.14E). These results suggest that miR-489 not only 
regulates estrogen signaling by inhibiting its nuclear localization but also by 
inhibiting its phosphorylation.  
 
3.2.7 MIR-489 KNOCK OUT CELLS SHOWS INCREASED SENSITIVITY TO 
ESTROGEN SIGNALING 
 
Knock-out model is an ideal tool to decipher molecular pathways affected 
by gene of interest as it enables reverse genetics and allows precise identification 
of gene functions. We utilized CRIPSR/Cas9 method to generate stable cell line 
with loss of function mutation in miR-489. Figure 3.15 outlines the strategy and 
experimental design to generate miR-489 knock out cell line. Our genotyping result 
showed successful editing at genomic locus of miR-489 (Fig. 3.15).  
As expected, our knock out clones demonstrated increased proliferation 
rate confirmed by MTT based cell viability assay (Figure 3.16A) and CFSE dye 
based proliferation assay (Figure 3.16B). Figure 3.16C shows morphology of 
knock cells. Surprisingly, knock clones were smaller in size compared to wild type 
cells. We validated these clones by examining expression of established targets 
of miR-489 using western blot analysis. Both clones showed increased protein 
expression of PTPN11, Cyclin A2, Cyclin D1 and p38 MAPK (Figure 3.17A). Both 
clones also showed increased phosphorylation of MAPK, AKT and ERα. These 
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results show hyper activation of ERα, MAPK and PI3K-AKT pathway in knock out 
cells. Indeed, knock out clones showed higher increase in expression of estrogen 
responsive genes upon E2 stimulation compared wild type cells (Figure 3.17B). 
We also observed increased estrogen receptor nuclear localization in knock out 
cells compared to wild type cells (Figure 3.18) and this nuclear localization was 
reverse by treatment with p38 inhibitor (Figure 3.19). In addition, knock out clones 
were hyper sensitive to estrogen stimulated growth. This hyper sensitivity was 
attenuated by MAPK, PI3K-AKT and p38 MAPK inhibitors (Fig. 3.20). These 
results suggest increased sensitivity of knock out cells is attributed to higher pERK, 
pAKT and p-p38MAPK expression. Knock out cells also showed significantly 
higher (more than 3-fold) cancer stem cells compared to wild type cells upon 
estrogen stimulation (Figure 3.21A and 3.21B). The increase in CSC population 
was only observed upon estrogen treatment further suggesting increased estrogen 
responsiveness upon loss of miR-489. 
3.2.8 MIR-489 SENSITIZES BREAST CANCER CELLS TO TAMOXIFEN 
 
Loss of miR-489 increases activity of MAPK and PI3K-AKT signaling 
pathway. In addition, we have previously established that loss of miR-489 also 
increases activity of HER2 signaling pathway. All these pathways are known to 
promote estrogen independent growth and promote tamoxifen resistance. 
Therefore, we examined role of miR-489 in tamoxifen resistance. We first 
examined effect of miR-489 on estrogen independent growth. MCF7 and T47D cell 
lines require estrogen for their proliferation and depletion of estrogen dramatically 
reduce their survival. Remarkably, inhibition of endogenous miR-489 significantly 
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increased survival under estrogen depletion (Fig. 3.22A and 3.22B). 
Mechanistically, inhibition of miR-489 increased estrogen independent 
phosphorylation of ERα through increased activation of MAPK and/or AKT (Fig. 
3.22C and 3.22D). We then examined expression of miR-489 and its host gene 
CALCR in two different tamoxifen resistant cell lines MCF7-TAMR and MCF7-
HER2. Both cell lines are derived differently but reported as tamoxifen resistant 
cell line. Remarkably, both cell lines showed significant down regulation of miR-
489 and CALCR (Figure 3.23A, 3.23B). Analysis of patient datasets obtained from 
kmplot showed high miR-489 expression predicts better survival in ER+ breast 
cancer patients who received endocrine therapy (Figure 3.23C). (Lanczky et al., 
2016). Similarly, higher CLACR expression also predicts better survival of ER+ 
breast cancer patient who received tamoxifen treatment (Figure 3.23D) (Mihaly et 
al., 2013). These analyses strongly suggest therapeutic potential role of miR-489 
in tamoxifen resistance. Consistent with clinical analysis, our MTT assay (Figure 
3.24A) and Clonogenic assay (Figure 3.24B) showed that miR-489 knock out cells 
are much more resistant to tamoxifen compared to WT cells. At higher 
concentration (7.5uM), we noticed 50% growth inhibition in WT cells while knock 
cells seemed almost unaffected. We the examined whether miR-489 restoration 
can sensitize tamoxifen resistant cell lines. We first modulated miR-489 expression 
in MCF7-HER2 cells. This cell line possesses de novo tamoxifen resistance due 
to hyper activation of HER2-PI3K-AKT signaling pathway. Intriguingly, although 
this cell line showed significant resistance to tamoxifen, they responded similarly 
as their sensitive counterpart (MCF7Vec) to miR-489 (Figure 3.25A). Forced 
  
  
 
 
70 
expression of miR-489 with tamoxifen sensitized resistant cell lines to Tamoxifen 
treatment (Figure 3.25B). Our clonogenic assay also showed significant 
sensitization upon co-treatment (Figure 3.25C). Conversely, inhibition of 
endogenous miR-489 in sensitive counterpart MCF7-Vec significantly protected 
cells from tamoxifen induced growth arrest and death (Figure 3.25D, 3.25E). 
Consistent with previous studies, our western blot analysis showed significant 
increase in ERα phosphorylation upregulation of HER2, AKT and ERK pathway 
(Shou et al., 2004). Restoration of miR-489 completely abolished activity of AKT 
and MAPK and attenuated ERα phosphorylation (Figure 3.25F). We also 
examined whether miR-489 can over acquired tamoxifen resistance. Like MCF7-
HER2, although this cell line showed significant resistance to tamoxifen, they 
responded similarly as their sensitive counterpart (MCF7-WT) to miR-489 (Figure 
3.26A). Forced expression of miR-489 with tamoxifen sensitized resistant cell lines 
to Tamoxifen treatment (Figure 3.26B). Conversely, inhibition of endogenous miR-
489 in sensitive counterpart MCF7-Vec significantly protected cells from tamoxifen 
induced growth arrest and death (Figure 3.26C). Our clonogenic assay also 
showed significant sensitization upon co-treatment (Figure 3.26D, 3.26E).  
Notably, 72 hours treatment with 5uM Tamoxifen had only marginal effect in both 
resistant cell lines while co-treatment of tamoxifen with miR-489 resulted in around 
50% growth inhibition in MCF7-TAM cell line and around 60% in MCF7-HER2 cell 
line. In summary, data shown here shows miR-489 targets multiple pathways 
associated with tamoxifen resistant and may provide a useful therapy sensitizer in 
tamoxifen resistant tumors.  
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3.3 SUMMARY AND DISCUSSION 
We report here that the miR-489 is positively regulated by the E2-ERα axis. 
However, since miR-489 inhibits activity of estrogen signaling, an interesting 
autoregulatory feedback loop can be proposed between ERα and the mir-489. We 
suggest that the role of the miR-489 is to balance the positive autoregulatory loop 
of E2-ERα axis by a negative feedback loop to control activity of ERα. Many 
autoregulatory feedback loops have been shown to regulate biological activity of a 
pathway. Similar autoregulatory loops involving miRNAs have been previously 
shown. For example, while miR-20a directly inhibits transcriptional activity of E2F1-
3 by directly binding to their 3’ UTR (Sylvestre et al., 2007). Interestingly, in our 
study we also observed a positive feedback loop between E2-ERα signaling and 
p38 MAPK. Estrogen activates p38 MAPK within few minutes upon binding to its 
receptor ERα.This activated p38 MAPK leads to nuclear translocation of ERα 
which is essential for its transcriptional activity. Similar observation has also been 
reported for ERK and AKT in regard to estrogen signaling. Like p38 MAPK, 
estrogen also activates AKT and ERK. Activated ERK and AKT then activates ERα 
by phosphorylating ERα at Ser1018 and Ser167. miR-489 regulates this positive 
feedback loop by inhibiting p38 MAPK, AKT and ERK activity (Figure 3.27). One 
interesting function of the negative feedback loop between ERα and the miR-489 
would be to create a fail-safe mechanism to avoid high ERα activity since, high 
ERα activity is potentially dangerous for the cell and is a major risk factor for breast 
cancer. In addition, miR-489 could serve as a potential prognostic marker in ER+ 
breast cancer where ER+ patients with low miRNA may possess hyper activation 
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of E2-ERα signaling and may potentially represent aggressive cancers. Indeed, 
clinical analysis of ER+ breast cancer patients suggest that patients with low miR-
489 expression have worse survival and have aggressive tumors. Although, 
endocrine therapy is the most effective way to treat ER+ breast cancer patients, 
20-30% of patients acquire resistance to this therapy. Besides, ER+ cancer 
patients with over expression of growth factors such as EGFR or HER2 possess 
de novo resistance against tamoxifen treatment (Chang, 2012). Our observations 
here indicate that miR-489 could potentially serve as a useful therapy sensitizer to 
treat tamoxifen resistance tumors. First, our study along with other reports showed 
miR-489 is significantly downregulated in tamoxifen resistant cell lines. Intriguingly, 
it is lost is both acquired and de novo resistant. Second, miR-489 directly inhibits 
AKT and MAPK pathways which are well established mechanism that promote 
estrogen independent growth and tamoxifen resistance. Third, miR-489 directly 
targets HER2 and its downstream molecules including SHP2 and AKT. 
Furthermore, autophagy and EMT has been reported to promote tamoxifen 
resistance. MCF7-TAM cells have been reported to undergone EMT and 
possesses higher basal autophagy (M. H. Lee et al., 2018; Nagelkerke et al., 2014; 
Ward et al., 2013). Inhibition of both processes have been previously shown to 
reverse the tamoxifen resistance. Interestingly, miR-489 has previously been 
reported reverse EMT through inhibition of Smad3 expression which leads to 
sensitization of doxorubicin. Previously, we have reported its role in autophagy and 
chemo-resistance(Soni et al., 2018). These data further support role of miR-489 in 
modulation of tamoxifen resistance.  
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In summary, these results suggest that miR-489 based therapy may be 
useful adjuvant therapy not only in resistant patients but also in treatment naïve 
patients since apart from inhibiting estrogen signaling, it also blocks HER2-PI3K-
AKT and MAPK pathways and may potentially reduce emergence of resistance to 
tamoxifen. These results contribute to the understanding of the complex regulatory 
pathways regulating ERα activity and are therefore may provide insights to develop 
novel ER+ breast cancer therapy. 
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Figure 3.1: miR-489 expression is positively correlated with expression 
of estrogen receptor. A. Expression of miR-489 in 13 different breast cancer cell 
lines representing 4 subtypes. Data are means of three replicates + SEM. B. 
Correlation of miR-489 with its host gene CALCR, estrogen receptor and 
progesterone receptor in clinical samples. C. Relative expression levels of miR-
489in breast cancer subtypes were compared using the one-way ANOVA analysis. 
The microarray data was extracted from previous publication [51, 52]. *, p value < 
0.05; **, p value < 0.01; ***, p value < 0.001.  ***, p<0.001; **, p<0.01; *, p<0.05. 
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Figure 3.2: E2-ERα signaling axis regulates expression of miR-489. A-D. 
Hormone starved T47D cells were stimulated with ethanol, E2 or P4 for indicated 
times. RNA was then isolated and expression of estrogen responsive genes along 
with miR-489 and CLACR was analyzed by qRT-PCR. E-F. Hormone starved MCF7 
(E) and BT474 (E) cell were stimulated with ethanol, E2 or E2+P4 for 72hrs followed 
by qRT-PCR analysis of miR-489 and CALCR expression. *, p value < 0.05; **, p 
value < 0.01; ***, p value < 0.001.  ***, p<0.001; **, p<0.01; *, p<0.05. 
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Figure 3.3: Estrogen deprivation down-regulates expression of miR-489. 
qRT-PCR analysis of miR-489 expression in complete media and in estrogen 
deprived medium. *, p value < 0.05; **, p value < 0.01; ***, p value < 0.001.  ***, 
p<0.001; **, p<0.01; *, p<0.05. 
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Figure 3.4: miR-489 inhibits estrogen induced proliferation. A. ER+ breast 
cancer cell lines were transfected with scr, mimic or inh for 72 hours and cell viability 
was measured using MTT assay.  B-C. Hormone starved MCF7 (B) and T47D (C) 
cell were stimulated with ethanol, E2 in presence of scr, mimic or inh for 6days 
followed and cell viability was measured using MTT assay. D-E. Relative survival at 
the end of 6day treatment in MCF7-Vec (D) and T47D (E). F. Hormone starved 
MCF7-Vec and T47D cells were treated with estrogen in presence of scr, mimic or 
inh for 8days and clonogenic assay was performed using crystal violet. *, p value < 
0.05; **, p value < 0.01; ***, p value < 0.001.  ***, p<0.001; **, p<0.01; *, p<0.05. 
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Figure 3.5: Depletion of miR-489 promotes estrogen induced cancer 
stem cell population. A-D. ER+ breast cancer cell lines MCF7-Vec (A) and T47D 
(C) were transfected with scr, mimic or inh for 6 days in presence of estrogen and 
cancer stem cell population was measured by flow cytometry using CD24 CD44 
surface markers. B & D. Quantification of CD24low CD44high cells. *, p value < 
0.05; **, p value < 0.01; ***, p value < 0.001.  ***, p<0.001; **, p<0.01; *, p<0.05. 
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Figure 3.6: Depletion of miR-489 promotes estrogen induced 
mammosphere formation. A-D. ER+ breast cancer cell lines MCF7-Vec (A) and 
T47D (B) were transfected with scr, mimic or inh for 6 days in presence of estrogen 
and cancer stem cell population was measured by mammosphere assay. C-D. 
Quantification of mammosphere forming efficiency in MCF7-Vec (C) and T47D (D) 
cells upon indicated treatment. *, p value < 0.05; **, p value < 0.01; ***, p value < 
0.001.  ***, p<0.001; **, p<0.01; *, p<0.05. 
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Figure 3.7: miR-489 inhibits estrogen induced gene transcription. A. 
ERE-reporter cell line T47D was transfected with scr, mimic or inh for 72 hours and 
luciferase activity was measured to report transcriptional activity of ERα. B. MCF7-
Vec cells were transiently transfected with scr, mimic or inh. After 24 hours cells 
were transfected with ERE-Luc reporter plasmid. 48 hours later luciferase activity 
was measured. C. Gene expression analysis of T47D cells showing down regulation 
of known estrogen responsive genes upon miR-489 over expression. *, p value < 
0.05; **, p value < 0.01; ***, p value < 0.001.  ***, p<0.001; **, p<0.01; *, p<0.05. 
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Figure 3.8: miR-489 inhibits expression of estrogen responsive genes. 
A-B. ER+ cell lines (A) and ER- cell lines (B) were transfected with scr or mimic for 
72 hours and qRT-PCR was performed to validate microarray results. *, p value < 
0.05; **, p value < 0.01; ***, p value < 0.001.  ***, p<0.001; **, p<0.01; *, p<0.05. 
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Figure 3.9: miR-489 inhibits estrogen dependent nuclear localization of 
ERα. A. ER+ cell line T47D (A) and MCF7-Vec (B) were transfected with scr, mimic 
or inh for 72 hours followed by immunofluorescence. DAPI was used as counter 
stain to stain nucleus. Images shown here are representative of three biological 
replicates.  
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Figure 3.10: p38 MAPK is a direct target of miR-489. A. ER+ cell lines 
MCF7, T47D and ER- cell line MDA-MB-468 were transfected with scr or mimic for 
72 hours. Phospho-p38 MAPK and total p38 MAPK expression was examined by 
western blot. GAPDH was used as a loading control. B. Schematic diagram of miR-
489 binding site in p38 MAPK UTR. C. Luciferase reporter plasmids containing wild 
type or mutant 3’UTR were co-transfected with vector or miR-489 overexpressing 
plasmids in HEK293 cells. Renilla luciferase reporter was used for normalization. *, p 
value < 0.05; **, p value < 0.01; ***, p value < 0.001.  ***, p<0.001; **, p<0.01; *, 
p<0.05. 
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Figure 3.11: p38 MAPK inhibition phenocopies effect of miR-489 on ER 
localization. A. Estrogen starved ER+ cell lines MCF7-Vec (A) and T47D (B) were 
transfected with scr or mimic for 72hrs or treated with DMSO or 10uM SB203580 for 
24hrs and treated for 15 min with E2. ERα localization was then examined by 
immunofluorescence. DAPI was used as counter stain to stain nucleus. Images 
shown here are representative of three biological replicates.  
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Figure 3.12: Positive feedback loop exists between E2-ERα axis and p38 
MAPK. A-B. ER+ cell lines MCF7-Vec (A) and T47D (B) were hormone starved for 
3days and then treated with E2 for indicated time points. Western blot analysis was 
then performed to examine p38 MAPK activation. GAPDH and total p38 MAPK were 
used as control. C. Hormone starved MCF7-Vec and T47D cells were treated with 
Ethanol or E2 in presence and absence of p38 MAPK inhibitor for 3 days. Viable 
cells were then fixed with methanol and stained with crystal violet. D. Proposed 
positive feedback loop between E2-ERα axis and p38 MAPK.  
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Figure 3.13: miR-489 reduces ERα phosphorylation by inhibiting MAPK 
and PI3K-AKT pathway. A. ER+ cell lines MCF7-Vec and T47D were transiently 
transfected with scr, mimic or inh for 3days. Total ERα and its phosphorylation level 
was inspected by western blot. GAPDH was used as loading control. B. ER+ cell 
lines MCF7-Vec and T47D were transiently transfected with scr, mimic or inh for 
3days. Phosphorylated forms of AKT and ERK kinases were checked by western 
blot. GAPDH was used as loading control. 
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Figure 3.14: miR-489 attenuates estrogen induced transcription and 
proliferation by Inhibiting p38 MAPK, ERK and PI3K-AKT pathways. A. 
ER+ cell lines MCF7-Vec and T47D were transiently transfected with scr, mimic or 
inh for 3days. Total ERα and its phosphorylation level was inspected by western 
blot. GAPDH was used as loading control. B. ER+ cell lines MCF7-Vec and T47D 
were transiently transfected with scr, mimic or inh for 3days. Phosphorylated forms 
of AKT and ERK kinases were checked by western blot. GAPDH was used as 
loading control. *, p value < 0.05; **, p value < 0.01; ***, p value < 0.001.  ***, 
p<0.001; **, p<0.01; *, p<0.05. 
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Figure 3.15: Schematic diagram demonstrating strategy and outline to 
generate miR-489 knock out cell line. Experimental design and strategy to 
generate miR-489 knock out cells. Figure shows guide RNA design strategy, guide 
RNA sequences and genotyping of edited clones. Red box indicates knock out 
clones.  
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Figure 3.16: miR-489 knock out cells display significant increase in 
proliferation rate compared to wild type cells.  A. Bright field microscopy 
showing morphology of wild type and knock out (KO) cells. B. WT and KO cells were 
seeded in six well and cultured for indicated time points, stained for 15min using 
1.4uM CFSE dye at 37C and analyzed by flow cytometry. C. Quantitative analysis 
showing relative decrease in CSFE dye. D. WT and KO cells were seeded in 96 well 
plate for 24hrs, 48hrs and 96hrs.  MTT based viability assay was performed to 
determine growth rate.  *, p value < 0.05; **, p value < 0.01; ***, p value < 0.001.  ***, 
p<0.001; **, p<0.01; *, p<0.05. 
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Figure 3.17: Characterization of knock out cells using western blot and 
qRT-PCR analysis. A Western blot analysis of miR-489 target proteins in WT and 
KO cells. GAPDH was used as s loading control. B. WT and knock out cells were 
hormone starved for 3days and stimulated with ethanol for 24 hrs. RNA was isolated 
and qRT-PCR was performed to examine expression of estrogen responsive genes.  
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Figure 3.18: miR-489 knock out cells displays increased nuclear 
localization of ERα.  WT and KO cells were seeded on cover slip in 6-well plate. 
Immunofluorescence microscopy was carried out 48-72 hrs post seeding to examine 
localization of ERα 
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Figure 3.19: Inhibition of p38 MAPK reverses localization of ERα.  KO 
cells were seeded on cover slip in 6-well plate and treated with SB203580 for 24hrs. 
Immunofluorescence microscopy was then carried out to examine localization of 
ERα 
 
  
  
 
 
93 
 
 
Figure 3.20: miR-489 knock out cells display hyper sensitivity to 
estrogen induced proliferation via over activation of p38 MAPK, MAPK 
and AKT pathways. A. Hormone starved WT and KO cells were seeded in 12-
well plate and treated with ethanol or E2 for 6-days and clonogenic ability was 
measured by crystal violet staining. B. Cell treated in A were collected and 10K cells 
were seeded in 6-well plate in estrogen containing media for colony formation assay. 
C. Hormone starved cells were seeded in 24-well plate and treated with E2 and 
indicated inhibitors. Clonogenic assay was performed at the end of 6-day treatment. 
D. MTT assay of cells treated same as in C. 
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Figure 3.21: Loss of miR-489 increases estrogen induced cancer stem 
cell expansion.  Hormone starved WT and KO cells were treated with ethanol or 
E2 for 6days and cancer stem cell population were analyzed using flow cytometry. 
Data are representative of two independent biological replicates. *, p value < 0.05; 
**, p value < 0.01; ***, p value < 0.001.  ***, p<0.001; **, p<0.01; *, p<0.05. 
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Figure 3.22: Loss of miR-489 increases estrogen independent growth.   
Hormone starved WT and KO cells were treated with ethanol or E2 for 6days and 
cancer stem cell population were analyzed using flow cytometry. Data are 
representative of two independent biological replicates. *, p value < 0.05; **, p value 
< 0.01; ***, p value < 0.001.  ***, p<0.001; **, p<0.01; *, p<0.05. 
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Figure 3.23: miR-489 is lost in tamoxifen resistant cell lines. A-B. MCF7-
HER2 cell line with de novo resistance against tamoxifen and MCF7-TAM cell line 
with acquired tamoxifen resistance were seeded in 6-well plate along with their 
sensitive counterpart. miR-489 and CALCR expression was inspected using qRT-
PCR.  C. Survival analysis of ER+ breast cancer patients who received endocrine 
treatment shows higher miR-489 expression level predicts better survival and 
prognosis. D. Survival analysis of ER+ breast cancer patients who received only 
tamoxifen treatment shows higher CALCR expression level predicts better survival 
and prognosis. *, p value < 0.05; **, p value < 0.01; ***, p value < 0.001.  ***, 
p<0.001; **, p<0.01; *, p<0.05. 
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Figure 3.24: Loss of miR-489 promotes tamoxifen resistance. A. Hormone 
starved WT and KO cells were treated with ethanol or different concentration of 
tamoxifen for 6days and cell viability was measured using MTT assay (A) and crystal 
violet (B). Data are representative of two independent biological replicates. *, p value 
< 0.05; **, p value < 0.01; ***, p value < 0.001.  ***, p<0.001; **, p<0.01; *, p<0.05. 
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Figure 3.25: miR-489 restoration overcomes de novo tamoxifen 
resistance. A. MCF7-Vec and MCF7-HER2 cells were transfected with scr, mimic 
or inh for 72 hours and MTT assay was performed to access cell viability. B. MCF7-
HER2 cells were treated with ethanol or different concentration of tamoxifen in 
presence or absence of mimic for 3days and cell viability was measured using MTT 
assay. C. Clonogenic assay showing survived colonies after MCF7-HER2 cells were 
treated for 6days with control siRNA or mimic in presence of tamoxifen. D. MCF7-
Vec cells were treated with ethanol or different concentration of tamoxifen in 
presence or absence of miR-489 inhibitor for 3days and cell viability was measured 
using MTT assay. E. Clonogenic assay showing survived colonies after MCF7-Vec 
cells were treated for 6days with control siRNA or miR-489 inhibitor in presence of 
tamoxifen. F. MCF7-Vec and MCF7HER2 cells were transfected with scr or mimic 
for 72 hours and western blot analysis was done to examine activation of ERα, 
MAPK and AKT. *, p value < 0.05; **, p value < 0.01; ***, p value < 0.001.  ***, 
p<0.001; **, p<0.01; *, p<0.05.  
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Figure 3.26: miR-489 restoration overcomes acquired tamoxifen 
resistance. A. MCF7-WT and MCF7-TAM cells were transfected with scr, mimic or 
inh for 72 hours and MTT assay was performed to access cell viability. B. MCF7-
TAM cells were treated with ethanol or different concentration of tamoxifen in 
presence or absence of mimic for 3days and cell viability was measured using MTT 
assay. C. MCF7-WT cells were treated with ethanol or different concentration of 
tamoxifen in presence or absence of miR-489 inhibitor for 3days and cell viability 
was measured using MTT assay. D. Clonogenic assay showing survived colonies 
after MCF7-TAM cells were treated for 6days with control siRNA or mimic in 
presence of tamoxifen. E. Clonogenic assay showing survived colonies after MCF7-
WT cells were treated for 6days with control siRNA or miR-489 inhibitor in presence 
of tamoxifen. *, p value < 0.05; **, p value < 0.01; ***, p value < 0.001.  ***, p<0.001; 
**, p<0.01; *, p<0.05.  
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Figure 3.27: Proposed model depicting role of miR-489 in ER signaling 
and tamoxifen resistance. Estrogen binding to ERα activates p38 MAPK, ERK 
and AKT. Activation of p38 MAPK leads to nuclear localization of ERα. Activation of 
ERK and AKT phosphorylates ERα at Ser 118 and Ser 167 which are essential for 
transcriptional activity of ERα. This E2-ERα axis increases miR-489 expression level 
which then acts as a negative feedback loop to restrain estrogen mediated gene 
transcription and proliferation by inhibiting p38 MAPK, pERK and pAKT. Hyper 
activation of MAPK, HER2, PI3K-AKT pathways promotes estrogen independent 
growth and tamoxifen resistance. miR-489 may provide promising therapeutic 
option to sensitize tamoxifen resistant tumors.  
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CHAPTER 4 
SUMMARY AND CONCLUSION 
 Currently, clinical management of the breast cancer patients is largely 
based on the use of a standardized set of clinical and pathological criteria for 
diagnosis and prognosis. Cancer staging system is currently being used to 
estimate patient prognosis and guide the selection of effective treatments. 
However, due to complexity and heterogeneity, patients with the same diagnosis 
and pathological characteristics can show wide variability in clinical outcomes and 
response to treatment. Therefore, apart from novel therapeutic agents, discovery 
of molecular markers for more accurate classification of a patient’s risk of disease 
events (prognostic markers) and response to specific treatment options (predictive 
markers) is also essential for the betterment of treatment. Here, we examined role 
of miR-489 in breast cancer and report its potential application as a prognostic and 
predictive marker. Firstly, we report that miR-489 expression analysis may predict 
aggressiveness of ER+ breast cancer and response to tamoxifen therapy. 
Furthermore, it can also be useful predictive marker for survival and anthracycline 
response to breast cancer patient with 8q22 amplification. Patients with 8q22 
amplification exhibits increased autophagic flux and are resistant to anthracycline 
therapy. However, 8q22 amplified patients with high miR-489 displays better 
survival potentially due to autophagy inhibition and chemo-sensitization by miR-
489. 
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In addition, our results suggest potential therapeutic role of miR-489. 
Surprisingly, miR-489 functions as tumor suppressor miRNA in all the major 
subtypes of breast cancer. Intriguingly, miR-489 modulates major proliferation 
drivers responsible for breast cancer. Our studies show miR-489 inhibits estrogen 
singling, HER2, PI3K-AKT and MAPK signaling pathway. Along the same line, our 
clinical analysis suggests that patients with low miR-489 represent aggressive 
cancers. We also observed similar trend on breast cancer cell lines. Most cell lines 
with high miR-489 expression levels displays slower proliferation rate compared to 
cell lines with low miR-489 expression. Therefore, we propose that miR-489 may 
function as an endogenous proliferation regulator and its loss may potentially be 
useful for prediction of aggressiveness of breast cancer.   
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CHAPTER 5 
MATERIALS AND METHODS 
Cell culture and reagents 
MCF7, T47D and HCC1954 were purchased from ATCC in 2013. MDA-MB-
231, MDA-MB-468, MDA-MB361, Hs578T, ZR-75-1 and BT474 cells were 
obtained from Dr. Saraswati Sukuma, Johns Hopkins University, in 2008. MCF7 
vector and MCF7 HER2 cell lines were kindly provided by Dr. Rachel Schiff (Baylor 
College of Medicine). MCF7-WT and tamoxifen resistant cells MCF7-TAMR were 
obtained from Ozgur Sahin, University of South Carolina in 2018. Cells were grown 
under standard conditions. Cell lines were tested for Mycoplasma via PCR using 
the Universal Mycoplasma Detection Kit (ATCC). MDA-MB-231, MDA-MB-468, 
BT549 and Hs578T were cultured in DMEM containing 10% FBS. MCF7-Vec and 
MCF7-HER2 cells were cultured in DMEM containing 10% FBS with insulin. T47D, 
HCC1954, BT474 and ZR-75-were cultured in RPMI containing 10% FBS. MCF7-
WT and MCF7-TAMR cells were cultured in phenol red free low glucose DMEM 
supplemented with 10% FBS, non-essential amino acids and insulin. For estrogen 
deprivation studies, MCF7 cells were cultured in phenol red free DMEMF12 
supplemented with insulin and 10% charcoal stripped FBS. T47D cells were 
cultured in phenol red free RPMI and 10% charcoal stripped FBS.  All cells were 
cultured at 37°C in a humidified incubator containing 5% CO2.  
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RNA isolation and RT-PCR 
RNA isolation and Quantitative real-time RT-PCR analysis were performed 
using standard protocol (H. Chen, Chung, & Sukumar, 2004; H. Chen et al., 2008; 
Liu et al., 2015). The total RNA, including miRNA, was extracted from cells and 
tissues by using Trizol reagent (Thermo Scientific, Cat#5596026). Reverse-
transcription was performed by using M-MLV reverse Transcriptase (Thermo 
Scientific, Cat#28025013). RT² SYBR Green ROX FAST Mastermix
(Qiagen, Cat#330623) was used to detect and quantify genes. Relative 
expression was normalized to the endogenous control GAPDH or RNU48 using 
the 2−ΔΔCt method.  
cDNA preparation for miRNA analysis 
Poly A tail was added to RNA by using Poly A polymerase enzyme. cDNA was 
prepared by using polydT adaptor. The universal R was used as reverse primer 
for miRNA detection by qRT-PCR. Here is sequence of poly dT adaptor: 
GCGAGCACAGAATTAATACGACTCACTATAGGTTTTTTTTTTTTVN and 
Universal R: GCGAGCACAGAATTAATACGAC. 
siRNA, miRNA mimics and inhibitors  
miR-489 mimic (Cat#C-300749-07-0010), inhibitor (Cat#IH-303056-01-0002), 
scramble (Cat#CN-001000-01-50) and ATG5 siRNA (Cat#J-004374-07-0002) 
were purchased from Dharmacon. 
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Colony formation assay 
We transfected mimic-miR-489 and inhibitor-miR-489 in MCF7 and MD-
MBA-231 cells and incubated cells for 24 hr. After incubation, we collected all cells. 
For MCF-7 10000cells/well and for MD-MBA-231 4000cell/well were plated in 6 
well plates in triplicates in DMEM media containing 10% Fetal Bovine Serum 
(FBS).  After one week of incubation in 5% CO2, cells were washed with 1x 
phosphate-buffered saline (PBS) and fixed using 100% methanol. Once fixed, cells 
were washed again with 1x PBS and stained with 0.5% crystal violet. All the visible 
colonies were photographed and manually counted, and the average with standard 
error of mean was plotted using graphpad prism software. 
MTT Assay 
MTT reagent 3-(4, 5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT) was used to examine cell viability. Cells were seeded at a density of 4,000 
cells/well for MDA-MB-231; 5,000 cells/well for MCF7 & HCC1954 and 10,000 
cells/well for T47D in triplicate in 96-well plates. Cells transfected with either 
0.32µl/well scrambled, miR-489 mimics, or miR-489 Inhibitor by using 0.32µl/well 
Lipofectamine RNAi and incubated at 37 °C for 72 hr. Cells were seeded at a 
density of 13,000 cells/well in triplicate in 24-well plates. Cells transfected with 
either 1µl/well scrambled, miR-489 mimics, or miR-489 Inhibitor by using 1µl/well 
Lipofectamine RNAi and incubated at 37 °C for 72 hr.  MTT assay was performed 
according to mention above. At the end of the incubation media was removed and 
formazan precipitates were dissolved by adding 200 µl of DMSO in each well. OD 
values were measured at both 570 and 630 nm and final values were calculated 
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by subtracting OD630 from OD570.  These values for each time point were used to 
plot the growth curve for each clone using graphpad prism.   
Plasmid constructs  
3’ UTR of human LAPTM4B, ATG4A, ULK1, PTPN11, p38 MAPK and B-raf 
was amplified from genomic DNA and cloned into the pGL3-promoter vector at the 
same XbaI and FseI sites. For the mutation analysis, putative miR-489 target site 
within 3’UTR of predicted targets was mutated by Q5® High-Fidelity DNA 
Polymerase (NEB Cat# M0491). All sequences were verified by direct sequencing 
of the plasmids. LAPTM4B-mCherry was a kind gift from Dr. Thomas Blom and Dr. 
Elina Ikonen (Blom et al., 2015). pBABE-puro mCherry-EGFP-LC3B was a gift 
from Jayanta Debnath (Addgene plasmid # 22418) (N'Diaye et al., 2009). pcDNA-
ULK1 vector was generated by excising ULK1 from HA-hULK1 (Addgene plasmid 
# 31963) (Jung et al., 2009) using EcoR1 and Not1 restriction enzymes.  
Stable Cell line generation  
293T cells were transfected with 3μg of pBABE-puro mCherry-EGFP-LC3B  
(Addgene #22418, provided through the courtesy of Dr. Jayanta Debnath), 3μg of 
VSVG plasmid and 2.5μg of ECO plasmid using 17μl of Lipofectamine2000 for 48 
hours. After 48 hours, supernatants were collected and spin down at 10,000 RPM 
at 4 °C to discard any cell debris. MDA-MB -231 cells were infected with virus for 
48 hours. Infected cells were treated with puromycin for one week.    
Stable cell line expressing ULK1 and LAPTM4B were generated using 
pcDNA-ULK1 vector, LAPTM4B-mCherry vector and pCDNA-LAPTM4B vectors. 
MDA-MB-231 cells were transfected with 2.5ug of vector using Lipofetamine 2000. 
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48-72hrs post transfection, cells were subjected to selection using G418 for 6-8 
days. Survived pool was then tested and used for further studies.  
miR-489 knock out cells were generated using pCAS9-GFP plasmid kindly 
provided by Dr. Philips Backhauls and gBlock guide RNA (Integrated DNA 
Technologies, IDT). T47D cells were co-transfected with pCAS9-GFP and two 
gBlock guide RNA for 48 hours. Cells were then harvested and subjected to 
Fluorescence-activated cell sorting (FACS) to collect GFP positive cells. GFP+ve 
cells were then seeded in 96 well plate at single cell per well dilution and amplified. 
Each single cell colonies were then screened for miR-489 deletion using 
genotyping. Potential clones were then validated by examining for miR-489 
expression using qRT-PCR and for miR-489 target expression using western blot 
analysis.  
Luciferase assay 
Luciferase assay was performed as mentioned earlier (H. Chen et al., 2008; 
H. Chen et al., 2007; Liu et al., 2015). Briefly, HEK293 cells were seeded at 6.5 x 
104 cells/well 24 h prior to the transfection in a 24 well plate. Cells were transfected 
with 50ng of pGL3 promoter vector containing wild type 3’UTR or mutated 3’UTR 
of potential target genes, 50ng of pRL-TK (Renilla luciferase vector-Promega) and 
100ng of miR-489 pcDNA 3.1 vector or empty pcDNA 3.1 vector. After 72 hrs post 
transfection, luciferase activity was measured using Dual-luciferase reporter assay 
system (Promega Cat# E1980) as per manufacturer’s instructions and normalized 
to the levels of Renilla luciferase activity.  
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Microarray analysis  
T47D cells were seeded in 6-well culture dish, treated with 28nM scramble 
miRNA or miR-489 mimic for 72hrs. RNA was extracted with Trizol reagent, 
followed by clean-up and DNase I treatment with QIAGEN RNeasy mini kit in 
accordance with the prescribed protocol provided with the kit. Quality control was 
performed with Agilent Bioanalyser before performing microarray. The data were 
normalized using the default quantile normalization with R-bioconductor package 
lumi version 3.2.2. The microarray data in this manuscript is available on the GEO 
database (GSE99728). A subset of identified genes was validated by q-PCR. 
Autophagy and cell viability assays 
Breast cancer cells were transfected with 28nM scr, mimic or inh, for 68hrs, 
and then treated with Bafilomycin A1 (400nM) or DMSO for 4hrs. The levels of 
LC3B-I/II and SQSTM1 protein expression were assayed by western blot. MDA-
MB-231 cells were transfected with scr, mimic or inhibitor for 24hrs and then 
treated with 3-MA for 48hrs. Autophagic flux was then assessed by examining 
LC3B-II and p62 expression using western blot. MDA-MB-231 cells stably 
expressing mCherry-EGFP-LC3B fusion protein were transfected with scr or mimic 
for 48hrs and assayed for co-localization of red and green punta using confocal 
microscopy.  
To study effect of miR-489 on cell survival, indicated cell lines were first 
seeded in 96 well plate in triplicate and transfected with 28nM scr or mimic. Cell 
viability assay was performed using MTT reagent at 72hrs. To assess effect of 
miR-489 under metabolic stress, MDA-MB-231, HCC1954 or T47D cells were 
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seeded in 96-well plate. Cells were transfected with scr, mimic or inh in complete 
media or in low serum. Cell viability assay was performed using MTT reagent at 
indicated time points. Expression of cleaved caspase 3, LC3B and p62 was 
analyzed using western blot. To study role of autophagy in miR-489 induced 
sensitization under starvation, MDA-MB-231 cells were transfected with 9.3nM scr 
or mimic in complete media or low serum in presence or absence of 3-MA, siATG5 
or Bafilomycin A1 followed by cell viability assay using MTT reagent and western 
blot analysis to examine effect on autophagy and apoptosis. To examine effect of 
miR-489 on doxorubicin induced cytoprotective autophagy, MDA-MB-231 and 
HCC1954 cells were transfected with 28nM scr or mimic with or without 
doxorubicin. Protein was isolated 72hrs post treatment and western blot was 
performed. 
Chemo-sensitization Assays 
To study doxorubicin localization, cells were treated with 28nM scr or mimic 
for 24hrs then treated with 0.5uM doxorubicin for 48hrs followed by confocal 
microscopy. MDA-MB-231 cells were transfected with 9.3nM scr or mimic for 24 
hours and treated with indicated concentration of doxorubicin in presence or 
absence of 3-MA (5mM), siATG5 (50nM) or Bafilomycin A1 (50nM) for 48 hours 
and cell proliferation was measured by MTT assay to examine role of autophagy 
inhibition in miR-489 mediated doxorubicin sensitization. To assess lysosomal 
integrity, MDA-MB-231 cells were transfected with 28nM scr or mimic and stained 
with Acridine orange (1µg/ml) for 20min followed by flow cytometry and confocal 
microscopy.   
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Preparation of miR-489-delivering nanoparticle 
Liposomes were prepared as described elsewhere with slight modifications (S. D. 
Li, Chono, & Huang, 2008; S. D. Li & Huang, 2006). Briefly, cationic liposomes 
consisting of DOTAP and cholesterol (2:1 molar ratio) were prepared using the 
thin-film hydration method. The film was hydrated with nuclease free water and 
sonicated using probe sonicator for 15min. The lipid concentration adjusted at 
10mg/ml. For miRNA-nanoparticles preparation, 231.4μls of cationic liposomes 
and 90μls of miRNA were mixed in final volume of 1 ml nuclease free water. The 
miRNA-liposomes were allowed to stand at room temperature for 10 min. miRNA-
nanoparticles were further decorated with sodium hyaluronate by adding 128.56μls 
of 1mg/ml sodium hyaluronate solution and kept at room temperature for another 
10min. The samples were condensed using Millipore centrifugal filter units.  
Xenograft experiments  
Six weeks old Athymic Female nude mice were purchased from Envigo. All mice 
were handled and maintained under supervision of veterinarian in accordance with 
institutional guidelines and under a University of South Carolina Institutional 
Animal Care and Use Committee (IACUC) approved protocol. All mice were 
subcutaneously injected with 1 x 106  MDA-MB-231 cells left flank of each mice 
(n=5/group). Mouse were randomly distributed in four groups when tumor size 
reached 50-100mm3. The mice were administered with control nanoparticles or 
miR-489 loaded nanoparticles every third day. Doxorubicin (4mg/kg) was 
administered day after injection of miRNA. Tumor volumes were calculated by 
measuring length and width every third day. After 3 weeks, all mice were sacrificed 
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and tumors were extracted after euthanizing all animals. Tumor volumes were 
calculated by modified ellipsoidal formula (1/2(lxw2)). 
Clinical samples 
Human breast cancer tissue samples were obtained through the South Carolina 
Tissue Bank with approval from the Institutional Review Board at the University of 
South Carolina. Tissue samples were randomly collected from patients who were 
diagnosed with invasive breast ductal carcinoma between 2003 and 2007. RNA 
was isolated from tumors samples and expression of miR-489, ULK1 and 
LAPTM4B was analyzed by qRT-PCR. Demographic and histopathology data of 
the patient samples are listed in Supplementary table 2.  
Estrogen and progesterone treatment  
To examine effect of estrogen and progesterone on gene expression and 
proliferation cells were first cultured in estrogen deprivation condition for 3-6 days. 
For estrogen deprivation, MCF7 cells were cultured in phenol red free DMEMF12 
supplemented with insulin and 10% charcoal stripped FBS. T47D cells were 
cultured in phenol red free RPMI and 10% charcoal stripped FBS. Cells were then 
trypsinzed and seeded in desired cell culture dish and treated with estrogen and/or 
progesterone for indicated amount of time.  
Flow Cytometry.  
CD24 and CD44 antibodies (BD Biosciences) were used to examine cancer stem 
cell population. After the treatment cells were harvested and washed with PBS. 
Cells were then resuspended in 1X PBS+2% FBS solution and counted using 
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Biorad cell counter. 200K cells from each sample were transferred to fresh tube, 
centrifuged and resuspended in 100uls of 1X PBS+2% FBS. Cells were incubated 
with CD24-PE and CD44-FITC antibodies for 30min with mixing every 10 minutes. 
Cells were washed with PBS at the end of incubation, resuspended in 1X PBS+2% 
FBS and read in BD Accuri C6 flow cytometer. To assess lysosomal integrity, 
MDA-MB-231 cells were transfected with 28nM scr or mimic and stained with 
Acridine orange (1µg/ml) for 20min. Cells were then washed and read using BD 
C6 Accuri flow cytometer.  
Mammosphere Assay.  
Cells were trypsinized and mechanically separated and passed through 40-μm 
filters to obtain single cell suspensions. Cells were plated at 10,000 cells per plate 
density in super–low-attachment plates in mammosphere media and cultured for 
6-8 days. Quantification of mammosphere numbers was accomplished by 
transferring in 96 well plate. 
Immunofluorescence. 
After indicated treatment, cells were washed with 1X PBS and fixed using 4% 
paraformaldehyde for 15minutes. Cells were washed thrice with 1X PBS and 
blocked using 1% Rat Serum, 0.01% triton X-100 and 1X PBS for 1 hour at room 
temperature. Cells were then incubated overnight with ERα antibody (Santacruz 
biotechnology) at 4 C. Next day, cells were washed with PBS thrice and incubated 
with Alexa fluor 594 goat anti-rabbit IgG H&L (Thermo scientific) for 1 hour at room 
temperature. After 3 washes with PBS, cells were counterstained with DAPI for 12 
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minutes and mounted on slide. Cells were then imaged using confocal microscope 
using cy3 and DAPI channel.  
Generation of knock out cells  
CRISPR/Cas9 gene editing method was used to generate miR-489 knock out cell 
line. Two guide RNAs flanking pre-miR-489 were designed using guide RNA 
designing tool (cripsr.mit.edu). G-block guide RNAs were purchased IDT 
technologies and Cas9-GFP plasmid was obtained from Dr. Philip Buckhaults. G-
block guide RNA and Cas9-GFP were co-transfected in T47D cells using T47D 
avalanche transfection reagent (ez biosystem). 72 hours post transfection, GFP 
positive cells were sorted using Fluorescent activated cell sorter. Sorted cells were 
then diluted to single cell and seeded in 6 96-well plate. Rest of the cells were 
seeded on 10-cm dish. Colonies grown from single clone were then expanded and 
screened for miR-489 deletion using genotyping.   
Western Blotting 
Protein extracts were obtained from whole cell lysates from breast cancer cell lines 
or mammary epithelial cells from mouse mammary gland. Isolation of protein in-
vitro was performed using M-PER (mammalian protein extraction reagent, 
Thermofisher, Grand Island, NY) with a protease inhibitor (Sigma, St. Louis, MO) 
following manufacturer’s instructions. Proteins were separated on 7% precast 
acrylamide gels, transferred to nitrocellulose blots, and probed with primary with 
antibodies protein of interest. Blots were incubated with primary antibodies 
overnight at 4ºC, washed with PBS/0.01% Tween-20, probed with HRP-
conjugated secondary antibody (Bio-rad, Hercules, CA) for 1 hour at room 
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temperature, washed, and visualized with ECL enhanced chemiluminescence kit 
(ThermoFisher Scientific Cat#). Blots were visualized using either the GE 
ImageQuant LAS 4000 (GE Healthcare Bio-Sciences, Pittsburgh, PA). As internal 
controls for equal loading, blots were re-probed with either Hrp-conjugated Anti-β-
actin (Santacruz Biotechnology, Santa Cruz, CA) or Anti-GAPDH Rabbit pAb 
(Santa Cruz Biotechnology, Santa Cruz, CA) after stripping the blot with a mild 
stripping buffer. Western images were quantified using GE ImageQuant Software. 
All primary antibodies were obtained from cell signaling. DEK was purchased from 
protein technology.  
Histology  
Tumor-bearing mice were sacrificed, and tumor specimens were fixed in freshly 
prepared 4% paraformaldehyde in PBS, pH 7.2. Tissue blocks were embedded in 
paraffin, 5 μm sections obtained and then stained with hematoxylin and eosin 
(H&E) (VWR, West Chester, PA) for visual examination.  
Immunohistochemistry 
Immunohistochemistry (IHC) was performed using 5 μM sections of xenografted 
tumor, spontaneous tumor and mammary gland fixed in Formalin overnight. 
Parraffin-embedded tissue sections on poly-L-lysine-coated slides were dewaxed 
in xylene (2 x 5 minutes) and rehydrated by washing in decreasing concentration 
of ethanol: 2 x 3 minutes in 100 percent ethanol, 2 x 3 minutes 95 percent ethanol 
and 1 x 3 minutes 75 percent ethanol. Antigen reterival was carried out by 
incubating slides in preheated citrate buffer (95 °C, pH6) for 30 minutes. Sections 
were blocked with 3 percent peroxide for 10 minutes. Sections were blocked with 
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0.1 percent BSA/PBS buffer for 1 hr at room temperature. Primary antibodies Ki-
67 (cell signaling Cat#9027) and LAPTM4B (Cat#2242). For, mouse tissue, Ki-67 
was obtained from BD (Cat#550609). Antibody for SHP2 was obtained from 
protein tech (Cat#24570-1-AP). All antibody dilutions were used accordingly 
instruction. All primary antibody was incubated for overnight at 4 C. Unbound 
antibodies were removed by using 0.1 percent tween/PBC buffer three times. 
Sections were incubated with anti-rabbit or mouse biotinylated antibody. Signal 
was amplified by using avidin-biotin complex (ABC kit) from Vector Laboratories. 
Sections were developed using DAB from Vector Laboratories.  For Ki-67 positive 
cell counting in tumors, total 1000 cells were counted from each individual tumor. 
For Ki-67 positive cell counting in mammary gland, 3 independent ducts and TEBs 
were counted from each mammary gland tissue. Total of 5 pairs of sister mice were 
used. 
Statistical Analysis 
The statistical analyses were conducted with R and GraphPad software packages. 
A Student t test or ANOVA test was used for comparison of quantitative data. The 
clinical effect of the gene expression profiles of miR-489 in the patients with 8q22 
gain/amplified tumor was evaluated using a published data set containing 1302 
breast cancer patients (Dvinge et al., 2013; Gray & Druker, 2012) The median 
expression value was used as the cutoff to classify miR-489 expression as high or 
low. Recurrence-free survival was estimated using the Kaplan-Meier method and 
compared with log-rank test. The linear correlations between miR-489 and 
potential target genes expression in primary breast cancer tissues were evaluated 
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with Pearson correlation coefficient analysis. Values of P < 0.05 were considered 
significant. 
Chi-square tests were made with the Schoenfeld residuals to check the 
proportional hazard assumption of the selected model. Values of P < 0.05 were 
considered significant. 
All data are shown as the mean ± standard deviation (SD); comparisons of 
two groups were analyzed using the two-tailed t-test with Welch’s correction using 
GraphPad Prism version 5.00 for Windows, (GraphPad Software, San Diego 
California USA, www.graphpad.com). P-values of p<0.05, p<0.01, and p<0.001 
are indicated with (*), (**), and (***), respectively, and all considered statistically 
significant.  
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